https://spypharm.com/rss/category/pharmaceutical SpyPharm | Pharmaceutical News, Developments & Trends & : Pharmaceutical en Copyright 2023 Spypharm & All Rights Reserved. https://spypharm.com/ec-approves-beones-tevimbra-for-nasopharyngeal-carcinoma https://spypharm.com/ec-approves-beones-tevimbra-for-nasopharyngeal-carcinoma Sun, 13 Jul 2025 06:00:14 -0400 spectro https://spypharm.com/fda-publishes-more-than-200-archived-crls-for-transparency https://spypharm.com/fda-publishes-more-than-200-archived-crls-for-transparency Sun, 13 Jul 2025 06:00:14 -0400 spectro https://spypharm.com/igi-and-abbvie-sign-licence-deal-for-cancer-and-autoimmune-therapy https://spypharm.com/igi-and-abbvie-sign-licence-deal-for-cancer-and-autoimmune-therapy Fri, 11 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/modular-manufacturing-the-key-to-unlocking-mrna-expansion https://spypharm.com/modular-manufacturing-the-key-to-unlocking-mrna-expansion Fri, 11 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/fda-gives-tsnd-201-breakthrough-therapy-designation-for-ptsd https://spypharm.com/fda-gives-tsnd-201-breakthrough-therapy-designation-for-ptsd Fri, 11 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/how-to-remain-a-top-cdmo-in-adc-led-oncology https://spypharm.com/how-to-remain-a-top-cdmo-in-adc-led-oncology Fri, 11 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/lupin-and-zentiva-in-licence-and-supply-deal-for-certolizumab-pegol https://spypharm.com/lupin-and-zentiva-in-licence-and-supply-deal-for-certolizumab-pegol Fri, 11 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/merck-agrees-to-acquire-verona-pharma-for-10bn https://spypharm.com/merck-agrees-to-acquire-verona-pharma-for-10bn Fri, 11 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/the-unsustainability-of-clinical-trials-and-need-for-transformative-change https://spypharm.com/the-unsustainability-of-clinical-trials-and-need-for-transformative-change Fri, 11 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/enhancing-solubility-of-targeted-protein-degraders-better-strategies-for-bioavailability https://spypharm.com/enhancing-solubility-of-targeted-protein-degraders-better-strategies-for-bioavailability Fri, 11 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/cto-east-coast-2025-global-oncology-cell-therapy-market-to-hit-25bn-by-2031 https://spypharm.com/cto-east-coast-2025-global-oncology-cell-therapy-market-to-hit-25bn-by-2031 Fri, 11 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/real-world-evidence-as-a-strategic-access-lever-in-rare-disease-drug-development https://spypharm.com/real-world-evidence-as-a-strategic-access-lever-in-rare-disease-drug-development Fri, 11 Jul 2025 06:00:15 -0400 spectro https://spypharm.com/chugai-and-gero-link-on-antibody-drugs-for-age-related-conditions https://spypharm.com/chugai-and-gero-link-on-antibody-drugs-for-age-related-conditions Wed, 09 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/swissmedic-approves-novartis-malaria-medicine-for-babies https://spypharm.com/swissmedic-approves-novartis-malaria-medicine-for-babies Wed, 09 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/gsk-acquires-efimosfermin-alfa-from-boston-pharma-for-2bn https://spypharm.com/gsk-acquires-efimosfermin-alfa-from-boston-pharma-for-2bn Wed, 09 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/fda-approves-kalvistas-ekterly-for-hereditary-angioedema https://spypharm.com/fda-approves-kalvistas-ekterly-for-hereditary-angioedema Wed, 09 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/cto-east-coast-2025-navigating-shifting-regulatory-environment-hinges-on-close-alignment https://spypharm.com/cto-east-coast-2025-navigating-shifting-regulatory-environment-hinges-on-close-alignment Wed, 09 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/research-warns-of-rising-hiv-cases-in-africa-amid-global-funding-cuts https://spypharm.com/research-warns-of-rising-hiv-cases-in-africa-amid-global-funding-cuts Wed, 09 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/swissmedic-approves-ifinwil-for-children-with-high-risk-neuroblastoma https://spypharm.com/swissmedic-approves-ifinwil-for-children-with-high-risk-neuroblastoma Wed, 09 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/leading-medical-groups-sue-rfk-jr-and-hhs-over-hostile-vaccine-policies https://spypharm.com/leading-medical-groups-sue-rfk-jr-and-hhs-over-hostile-vaccine-policies Wed, 09 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/pulmonary-arterial-hypertension-market-to-reach-935bn-across-7mm-by-2034 https://spypharm.com/pulmonary-arterial-hypertension-market-to-reach-935bn-across-7mm-by-2034 Wed, 09 Jul 2025 06:00:16 -0400 spectro https://spypharm.com/jcr-pharma-and-alexion-partner-on-just-aav-gene-therapy-platform https://spypharm.com/jcr-pharma-and-alexion-partner-on-just-aav-gene-therapy-platform Wed, 09 Jul 2025 06:00:15 -0400 spectro https://spypharm.com/alembic-pharmaceuticals-acquires-utility-therapeutics https://spypharm.com/alembic-pharmaceuticals-acquires-utility-therapeutics Mon, 07 Jul 2025 06:00:13 -0400 spectro https://spypharm.com/cdmo-insights-podcast-series-our-experience-is-your-strength-episode-1-formulation https://spypharm.com/cdmo-insights-podcast-series-our-experience-is-your-strength-episode-1-formulation Mon, 07 Jul 2025 06:00:13 -0400 spectro https://spypharm.com/theratechnologies-shares-surge-25-amid-254m-future-pak-takeover https://spypharm.com/theratechnologies-shares-surge-25-amid-254m-future-pak-takeover Sat, 05 Jul 2025 06:00:24 -0400 spectro https://spypharm.com/uk-government-reveals-10-year-plan-for-nhs https://spypharm.com/uk-government-reveals-10-year-plan-for-nhs Sat, 05 Jul 2025 06:00:24 -0400 spectro https://spypharm.com/bioversys-and-shionogi-agree-to-develop-ansamycin-leads https://spypharm.com/bioversys-and-shionogi-agree-to-develop-ansamycin-leads Sat, 05 Jul 2025 06:00:24 -0400 spectro https://spypharm.com/regeneron-nabs-dosing-edge-with-lynozyfics-fda-approval-in-multiple-myeloma https://spypharm.com/regeneron-nabs-dosing-edge-with-lynozyfics-fda-approval-in-multiple-myeloma Sat, 05 Jul 2025 06:00:24 -0400 spectro https://spypharm.com/five-lessons-from-biopharma-companies-data-transformation-journeys https://spypharm.com/five-lessons-from-biopharma-companies-data-transformation-journeys Sat, 05 Jul 2025 06:00:23 -0400 spectro https://spypharm.com/modella-ai-and-astrazeneca-link-for-cancer-clinical-development https://spypharm.com/modella-ai-and-astrazeneca-link-for-cancer-clinical-development Sat, 05 Jul 2025 06:00:23 -0400 spectro https://spypharm.com/big-pharma-braces-for-revenue-headwinds-as-patent-expiries-loom https://spypharm.com/big-pharma-braces-for-revenue-headwinds-as-patent-expiries-loom Sat, 05 Jul 2025 06:00:23 -0400 spectro https://spypharm.com/biocons-denosumab-biosimilars-gain-eu-marketing-authorisation https://spypharm.com/biocons-denosumab-biosimilars-gain-eu-marketing-authorisation Sat, 05 Jul 2025 06:00:23 -0400 spectro https://spypharm.com/astrazenecas-imfinzi-approved-in-europe-for-muscle-invasive-bladder-cancer https://spypharm.com/astrazenecas-imfinzi-approved-in-europe-for-muscle-invasive-bladder-cancer Sat, 05 Jul 2025 06:00:23 -0400 spectro https://spypharm.com/brii-biosciences-and-joincare-sign-licence-agreement-for-brii-693 https://spypharm.com/brii-biosciences-and-joincare-sign-licence-agreement-for-brii-693 Sat, 05 Jul 2025 06:00:23 -0400 spectro https://spypharm.com/merck-concludes-springworks-acquisition-for-34bn https://spypharm.com/merck-concludes-springworks-acquisition-for-34bn Thu, 03 Jul 2025 06:00:24 -0400 spectro https://spypharm.com/cell-and-gene-therapy-the-vital-role-of-logistics https://spypharm.com/cell-and-gene-therapy-the-vital-role-of-logistics Thu, 03 Jul 2025 06:00:24 -0400 spectro https://spypharm.com/podcast-the-importance-of-social-determinants-of-health-sdoh https://spypharm.com/podcast-the-importance-of-social-determinants-of-health-sdoh Thu, 03 Jul 2025 06:00:23 -0400 spectro https://spypharm.com/fda-approves-dizals-zegfrovy-to-treat-adults-with-nsclc https://spypharm.com/fda-approves-dizals-zegfrovy-to-treat-adults-with-nsclc Thu, 03 Jul 2025 06:00:23 -0400 spectro https://spypharm.com/sanofi-agrees-to-invest-25m-in-adagene https://spypharm.com/sanofi-agrees-to-invest-25m-in-adagene Thu, 03 Jul 2025 06:00:23 -0400 spectro https://spypharm.com/navigating-the-ai-regulatory-maze-why-91-of-life-sciences-professionals-feel-lost https://spypharm.com/navigating-the-ai-regulatory-maze-why-91-of-life-sciences-professionals-feel-lost Thu, 03 Jul 2025 06:00:23 -0400 spectro https://spypharm.com/protecting-patients-data-is-vital-for-nhs-single-health-record-system https://spypharm.com/protecting-patients-data-is-vital-for-nhs-single-health-record-system Thu, 03 Jul 2025 06:00:23 -0400 spectro https://spypharm.com/analysis-shows-yeztugo-approval-a-momentous-step-for-hiv-prevention https://spypharm.com/analysis-shows-yeztugo-approval-a-momentous-step-for-hiv-prevention Thu, 03 Jul 2025 06:00:23 -0400 spectro https://spypharm.com/trump-tax-bill-estimated-to-cut-medicaid-spend-by-1trn-passes-us-senate https://spypharm.com/trump-tax-bill-estimated-to-cut-medicaid-spend-by-1trn-passes-us-senate Thu, 03 Jul 2025 06:00:23 -0400 spectro https://spypharm.com/vertex-wins-european-approval-for-alyftrek-bolstering-cystic-fibrosis-stronghold https://spypharm.com/vertex-wins-european-approval-for-alyftrek-bolstering-cystic-fibrosis-stronghold Thu, 03 Jul 2025 06:00:23 -0400 spectro https://spypharm.com/sobi-gains-fda-approval-for-gamifant-to-treat-hlhmas https://spypharm.com/sobi-gains-fda-approval-for-gamifant-to-treat-hlhmas Tue, 01 Jul 2025 06:01:21 -0400 spectro https://spypharm.com/torrent-pharmaceuticals-to-acquire-stake-in-jb-pharma-for-3bn https://spypharm.com/torrent-pharmaceuticals-to-acquire-stake-in-jb-pharma-for-3bn Tue, 01 Jul 2025 06:01:21 -0400 spectro https://spypharm.com/vetter-breaks-ground-on-285m-us-clinical-manufacturing-site https://spypharm.com/vetter-breaks-ground-on-285m-us-clinical-manufacturing-site Tue, 01 Jul 2025 06:01:20 -0400 spectro https://spypharm.com/fda-removes-safety-programme-for-car-t-therapies-to-boost-uptake https://spypharm.com/fda-removes-safety-programme-for-car-t-therapies-to-boost-uptake Tue, 01 Jul 2025 06:01:20 -0400 spectro https://spypharm.com/us-trade-tariffs-and-the-potential-impact-on-pharma-supply-chains https://spypharm.com/us-trade-tariffs-and-the-potential-impact-on-pharma-supply-chains Tue, 01 Jul 2025 06:01:20 -0400 spectro https://spypharm.com/ckd-anemia-market-expected-to-reach-53bn-across-the-7mm-by-2034 https://spypharm.com/ckd-anemia-market-expected-to-reach-53bn-across-the-7mm-by-2034 Tue, 01 Jul 2025 06:01:20 -0400 spectro https://spypharm.com/who-accuses-china-of-withholding-covid-19-genetic-data https://spypharm.com/who-accuses-china-of-withholding-covid-19-genetic-data Tue, 01 Jul 2025 06:01:19 -0400 spectro https://spypharm.com/fda-approves-takedas-gammagard-liquid-erc-for-primary-immunodeficiency https://spypharm.com/fda-approves-takedas-gammagard-liquid-erc-for-primary-immunodeficiency Tue, 01 Jul 2025 06:01:19 -0400 spectro https://spypharm.com/fda-approves-label-updates-for-bms-car-t-cell-therapies https://spypharm.com/fda-approves-label-updates-for-bms-car-t-cell-therapies Sun, 29 Jun 2025 06:00:14 -0400 spectro https://spypharm.com/viatris-gains-china-approval-for-yupelri-to-treat-copd https://spypharm.com/viatris-gains-china-approval-for-yupelri-to-treat-copd Sun, 29 Jun 2025 06:00:14 -0400 spectro https://spypharm.com/novo-nordisk-teams-up-with-weightwatchers-in-latest-telehealth-push https://spypharm.com/novo-nordisk-teams-up-with-weightwatchers-in-latest-telehealth-push Sun, 29 Jun 2025 06:00:14 -0400 spectro https://spypharm.com/why-cant-the-us-figure-out-weight-loss-drug-prices https://spypharm.com/why-cant-the-us-figure-out-weight-loss-drug-prices Sun, 29 Jun 2025 06:00:14 -0400 spectro https://spypharm.com/ai-in-drug-discovery-from-hypothetical-to-reality https://spypharm.com/ai-in-drug-discovery-from-hypothetical-to-reality Sun, 29 Jun 2025 06:00:14 -0400 spectro https://spypharm.com/navigating-uncertainty-the-future-of-vaccine-oversight-amid-cdc-firings https://spypharm.com/navigating-uncertainty-the-future-of-vaccine-oversight-amid-cdc-firings Fri, 27 Jun 2025 06:00:25 -0400 spectro https://spypharm.com/biocitys-sc0062-gains-nmpa-breakthrough-therapy-designation https://spypharm.com/biocitys-sc0062-gains-nmpa-breakthrough-therapy-designation Fri, 27 Jun 2025 06:00:24 -0400 spectro https://spypharm.com/uk-steps-up-with-125bn-gavi-vaccine-pledge-as-us-funding-disappears https://spypharm.com/uk-steps-up-with-125bn-gavi-vaccine-pledge-as-us-funding-disappears Fri, 27 Jun 2025 06:00:24 -0400 spectro https://spypharm.com/eli-lilly-receives-fda-approval-for-amyvid-label-update https://spypharm.com/eli-lilly-receives-fda-approval-for-amyvid-label-update Fri, 27 Jun 2025 06:00:24 -0400 spectro https://spypharm.com/how-ai-and-machine-learning-are-transforming-drug-discovery https://spypharm.com/how-ai-and-machine-learning-are-transforming-drug-discovery Fri, 27 Jun 2025 06:00:24 -0400 spectro https://spypharm.com/novartis-concludes-regulus-therapeutics-acquisition https://spypharm.com/novartis-concludes-regulus-therapeutics-acquisition Fri, 27 Jun 2025 06:00:24 -0400 spectro https://spypharm.com/gilead-eyes-kymeras-adhesive-cancer-drug-in-750m-deal https://spypharm.com/gilead-eyes-kymeras-adhesive-cancer-drug-in-750m-deal Fri, 27 Jun 2025 06:00:24 -0400 spectro https://spypharm.com/innovation-in-focus-highlights-from-the-two-day-london-biotechnology-show-2025 https://spypharm.com/innovation-in-focus-highlights-from-the-two-day-london-biotechnology-show-2025 Fri, 27 Jun 2025 06:00:24 -0400 spectro https://spypharm.com/porton-advanced-and-eva-pharma-collaborate-for-car-t-cell-therapies https://spypharm.com/porton-advanced-and-eva-pharma-collaborate-for-car-t-cell-therapies Fri, 27 Jun 2025 06:00:23 -0400 spectro https://spypharm.com/vor-bio-back-from-brink-with-autoimmune-drug-deal-rising-to-4bn https://spypharm.com/vor-bio-back-from-brink-with-autoimmune-drug-deal-rising-to-4bn Fri, 27 Jun 2025 06:00:23 -0400 spectro https://spypharm.com/fda-approves-astrazeneca-and-daiichi-sankyos-datroway-for-nsclc https://spypharm.com/fda-approves-astrazeneca-and-daiichi-sankyos-datroway-for-nsclc Wed, 25 Jun 2025 06:00:22 -0400 spectro https://spypharm.com/fda-genai-reviews-hinge-on-clarity-of-dossiers https://spypharm.com/fda-genai-reviews-hinge-on-clarity-of-dossiers Wed, 25 Jun 2025 06:00:21 -0400 spectro https://spypharm.com/overcoming-technical-challenges-in-gene-therapy-product-fill-finish-operations https://spypharm.com/overcoming-technical-challenges-in-gene-therapy-product-fill-finish-operations Wed, 25 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/zambon-gains-chinese-regulatory-authority-approval-for-fluimucil-iv https://spypharm.com/zambon-gains-chinese-regulatory-authority-approval-for-fluimucil-iv Wed, 25 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/navamedic-signs-agreement-to-acquire-dne-pharma https://spypharm.com/navamedic-signs-agreement-to-acquire-dne-pharma Wed, 25 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/hims-hers-shares-plummet-35-as-novo-nordisk-pulls-partnership-plug https://spypharm.com/hims-hers-shares-plummet-35-as-novo-nordisk-pulls-partnership-plug Wed, 25 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/revolution-medicines-partners-royalty-pharma-on-2bn-funding https://spypharm.com/revolution-medicines-partners-royalty-pharma-on-2bn-funding Wed, 25 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/fda-approves-sanofi-and-regenerons-dupixent-for-bullous-pemphigoid https://spypharm.com/fda-approves-sanofi-and-regenerons-dupixent-for-bullous-pemphigoid Wed, 25 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2025-i3-membrane https://spypharm.com/pharmaceutical-technology-excellence-awards-2025-i3-membrane Wed, 25 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/alzheimers-rd-resurgence-driven-by-168bn-in-acquisitions-in-2025ytd https://spypharm.com/alzheimers-rd-resurgence-driven-by-168bn-in-acquisitions-in-2025ytd Wed, 25 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/ec-approves-argenxs-efgartigimod-alfa-for-cidp-treatment https://spypharm.com/ec-approves-argenxs-efgartigimod-alfa-for-cidp-treatment Mon, 23 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/from-discovery-to-delivery-making-therapies-reach-patients-faster https://spypharm.com/from-discovery-to-delivery-making-therapies-reach-patients-faster Mon, 23 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/nsw-government-invests-1339m-in-life-changing-therapies https://spypharm.com/nsw-government-invests-1339m-in-life-changing-therapies Sat, 21 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/doh-abu-dhabi-and-sanofi-link-for-vaccine-development https://spypharm.com/doh-abu-dhabi-and-sanofi-link-for-vaccine-development Sat, 21 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/cns-innovator-oligonucleotide-licensing-value-up-339-from-2bn-in-2024 https://spypharm.com/cns-innovator-oligonucleotide-licensing-value-up-339-from-2bn-in-2024 Sat, 21 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/actio-gains-66m-to-advance-small-molecule-therapeutics-pipeline https://spypharm.com/actio-gains-66m-to-advance-small-molecule-therapeutics-pipeline Sat, 21 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/uk-and-us-governments-pursue-contrasting-vaccine-strategies https://spypharm.com/uk-and-us-governments-pursue-contrasting-vaccine-strategies Sat, 21 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/madrigal-poised-to-enter-european-mash-market-after-chmp-endorsement https://spypharm.com/madrigal-poised-to-enter-european-mash-market-after-chmp-endorsement Sat, 21 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/podcast-the-benefits-of-blockchain-in-healthcare https://spypharm.com/podcast-the-benefits-of-blockchain-in-healthcare Sat, 21 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/novartis-ribociclib-approved-in-canada-for-early-breast-cancer https://spypharm.com/novartis-ribociclib-approved-in-canada-for-early-breast-cancer Sat, 21 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/london-biotechnology-show-2025-novo-nordisk-harnesses-aiml-to-accelerate-drug-development-landscape https://spypharm.com/london-biotechnology-show-2025-novo-nordisk-harnesses-aiml-to-accelerate-drug-development-landscape Sat, 21 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/fda-cell-and-gene-therapy-director-exit-increases-volatility-for-sector https://spypharm.com/fda-cell-and-gene-therapy-director-exit-increases-volatility-for-sector Sat, 21 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/lisata-collaborates-with-gatc-health-on-drug-development https://spypharm.com/lisata-collaborates-with-gatc-health-on-drug-development Thu, 19 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/nhs-england-chair-suggests-england-can-learn-from-european-health-schemes https://spypharm.com/nhs-england-chair-suggests-england-can-learn-from-european-health-schemes Thu, 19 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/bavarian-nordic-nets-160m-from-priority-review-voucher-sale https://spypharm.com/bavarian-nordic-nets-160m-from-priority-review-voucher-sale Thu, 19 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/tisentos-melas-treatment-receives-fast-track-status-from-fda https://spypharm.com/tisentos-melas-treatment-receives-fast-track-status-from-fda Thu, 19 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/novo-nordisk-seeks-digital-health-partners-to-boost-glp-1ra-weight-loss-outcomes https://spypharm.com/novo-nordisk-seeks-digital-health-partners-to-boost-glp-1ra-weight-loss-outcomes Thu, 19 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/orion-and-glykos-extend-adc-collaboration https://spypharm.com/orion-and-glykos-extend-adc-collaboration Thu, 19 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/fda-commissioner-envisions-fewer-delays-more-clinical-trial-flexibility-and-ai-use https://spypharm.com/fda-commissioner-envisions-fewer-delays-more-clinical-trial-flexibility-and-ai-use Thu, 19 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/navigating-tariffs-and-diplomacy-the-future-of-india-us-pharmaceutical-trade https://spypharm.com/navigating-tariffs-and-diplomacy-the-future-of-india-us-pharmaceutical-trade Thu, 19 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/fda-creates-new-priority-review-voucher-scheme-to-boost-us-interests https://spypharm.com/fda-creates-new-priority-review-voucher-scheme-to-boost-us-interests Thu, 19 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/gilead-sciences-yeztugo-receives-approval-from-us-fda-for-hiv https://spypharm.com/gilead-sciences-yeztugo-receives-approval-from-us-fda-for-hiv Thu, 19 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/eha-2025-astrazenecas-surovatamig-is-potential-next-gen-bite-for-rr-b-all https://spypharm.com/eha-2025-astrazenecas-surovatamig-is-potential-next-gen-bite-for-rr-b-all Tue, 17 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/sarepta-and-roche-halt-dmd-gene-therapys-use-after-second-death https://spypharm.com/sarepta-and-roche-halt-dmd-gene-therapys-use-after-second-death Tue, 17 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/ethris-and-thermo-fisher-partner-on-mrna-solutions https://spypharm.com/ethris-and-thermo-fisher-partner-on-mrna-solutions Tue, 17 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/eha-2025-regenerons-lynozyfic-with-amgens-kyprolis-combo-emerges-for-rr-mm https://spypharm.com/eha-2025-regenerons-lynozyfic-with-amgens-kyprolis-combo-emerges-for-rr-mm Tue, 17 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/nice-approves-gsks-belantamab-mafodotin-for-blood-cancer https://spypharm.com/nice-approves-gsks-belantamab-mafodotin-for-blood-cancer Tue, 17 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/nextcure-and-simcere-partner-to-develop-sim0505-for-solid-tumours https://spypharm.com/nextcure-and-simcere-partner-to-develop-sim0505-for-solid-tumours Tue, 17 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/supernus-makes-depression-drug-play-with-795m-sage-buyout https://spypharm.com/supernus-makes-depression-drug-play-with-795m-sage-buyout Tue, 17 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/fda-approves-msds-keytruda-to-treat-head-and-neck-cancer https://spypharm.com/fda-approves-msds-keytruda-to-treat-head-and-neck-cancer Tue, 17 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/myasthenia-gravis-market-to-reach-103bn-across-7mm-by-2034 https://spypharm.com/myasthenia-gravis-market-to-reach-103bn-across-7mm-by-2034 Sun, 15 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/bharat-biotech-acquires-licence-for-gsks-shigella-vaccine-development https://spypharm.com/bharat-biotech-acquires-licence-for-gsks-shigella-vaccine-development Sun, 15 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/debiopharm-and-alkyon-link-for-radioligand-therapies-development https://spypharm.com/debiopharm-and-alkyon-link-for-radioligand-therapies-development Sun, 15 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/astrazeneca-taps-chinese-biotech-in-52bn-chronic-disease-research-deal https://spypharm.com/astrazeneca-taps-chinese-biotech-in-52bn-chronic-disease-research-deal Sun, 15 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/modernas-mrna-rsv-vaccine-wins-expanded-fda-approval-for-younger-adults https://spypharm.com/modernas-mrna-rsv-vaccine-wins-expanded-fda-approval-for-younger-adults Sun, 15 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/wes-streeting-29bn-nhs-boost-substantial-but-reform-still-needed https://spypharm.com/wes-streeting-29bn-nhs-boost-substantial-but-reform-still-needed Fri, 13 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/vutrisiran-marks-first-silencer-approved-for-attr-cm https://spypharm.com/vutrisiran-marks-first-silencer-approved-for-attr-cm Fri, 13 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/enterome-to-advance-eo2463-immunotherapy-with-19m-funding https://spypharm.com/enterome-to-advance-eo2463-immunotherapy-with-19m-funding Fri, 13 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/customs-simplified-the-need-to-streamline-pharma-shipments https://spypharm.com/customs-simplified-the-need-to-streamline-pharma-shipments Fri, 13 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/fda-approves-capsidas-cap-003-gene-therapy-for-parkinsons https://spypharm.com/fda-approves-capsidas-cap-003-gene-therapy-for-parkinsons Fri, 13 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/splicebio-secures-135m-for-gene-therapy-development https://spypharm.com/splicebio-secures-135m-for-gene-therapy-development Fri, 13 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/vaccine-sceptics-among-new-members-hired-by-rfk-jr-for-cdcs-vaccine-panel https://spypharm.com/vaccine-sceptics-among-new-members-hired-by-rfk-jr-for-cdcs-vaccine-panel Fri, 13 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/novo-nordisk-signs-812m-research-deal-with-deep-apple-for-non-glp-1-drugs https://spypharm.com/novo-nordisk-signs-812m-research-deal-with-deep-apple-for-non-glp-1-drugs Fri, 13 Jun 2025 06:00:19 -0400 spectro https://spypharm.com/fda-approves-label-expansion-of-abbvie-hepatitis-c-therapy https://spypharm.com/fda-approves-label-expansion-of-abbvie-hepatitis-c-therapy Fri, 13 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/biontech-bolsters-mrna-pipeline-with-125bn-curevac-acquisition https://spypharm.com/biontech-bolsters-mrna-pipeline-with-125bn-curevac-acquisition Fri, 13 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/aytu-biopharma-to-commercialise-exxua-for-mdd-in-the-us https://spypharm.com/aytu-biopharma-to-commercialise-exxua-for-mdd-in-the-us Wed, 11 Jun 2025 06:00:21 -0400 spectro https://spypharm.com/american-society-of-clinical-oncology-asco-annual-meeting-2025 https://spypharm.com/american-society-of-clinical-oncology-asco-annual-meeting-2025 Wed, 11 Jun 2025 06:00:21 -0400 spectro https://spypharm.com/outlooks-wet-amd-treatment-accepted-by-smc-for-nhs-scotland https://spypharm.com/outlooks-wet-amd-treatment-accepted-by-smc-for-nhs-scotland Wed, 11 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/odyssey-bails-on-public-listing-as-us-ipo-landscape-stutters https://spypharm.com/odyssey-bails-on-public-listing-as-us-ipo-landscape-stutters Wed, 11 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/mosanna-therapeutics-gains-80m-to-advance-osa-nasal-spray https://spypharm.com/mosanna-therapeutics-gains-80m-to-advance-osa-nasal-spray Wed, 11 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/rfk-jr-axes-vaccine-advisory-committee-members https://spypharm.com/rfk-jr-axes-vaccine-advisory-committee-members Wed, 11 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/msd-receives-fda-approval-for-enflonsia-to-prevent-rsv https://spypharm.com/msd-receives-fda-approval-for-enflonsia-to-prevent-rsv Wed, 11 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/ec-approves-alnylams-vutrisiran-for-attr-cm-treatment https://spypharm.com/ec-approves-alnylams-vutrisiran-for-attr-cm-treatment Wed, 11 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/fda-approves-yoltechs-yolt-101-for-familial-hypercholesterolemia https://spypharm.com/fda-approves-yoltechs-yolt-101-for-familial-hypercholesterolemia Wed, 11 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/podcast-ai-and-supervised-machine-learning-in-clinical-trials-part-2 https://spypharm.com/podcast-ai-and-supervised-machine-learning-in-clinical-trials-part-2 Wed, 11 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/the-european-market-access-lag-20212024 https://spypharm.com/the-european-market-access-lag-20212024 Mon, 09 Jun 2025 06:00:13 -0400 spectro https://spypharm.com/ec-approves-astrazenecas-acalabrutinib-combo-for-cll https://spypharm.com/ec-approves-astrazenecas-acalabrutinib-combo-for-cll Mon, 09 Jun 2025 06:00:13 -0400 spectro https://spypharm.com/ec-authorises-sydnexis-paediatric-myopia-treatment https://spypharm.com/ec-authorises-sydnexis-paediatric-myopia-treatment Sat, 07 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/bayer-subsidiary-vividion-secures-rights-to-werner-helicase-inhibitor https://spypharm.com/bayer-subsidiary-vividion-secures-rights-to-werner-helicase-inhibitor Sat, 07 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/akeso-gains-nmpa-approval-for-cadonilimab-to-treat-cervical-cancer https://spypharm.com/akeso-gains-nmpa-approval-for-cadonilimab-to-treat-cervical-cancer Sat, 07 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/dupixent-fuelled-atopic-dermatitis-market-sales-to-hit-224bn-by-2033 https://spypharm.com/dupixent-fuelled-atopic-dermatitis-market-sales-to-hit-224bn-by-2033 Sat, 07 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/mhra-warns-women-using-weight-loss-jabs-must-use-effective-contraception https://spypharm.com/mhra-warns-women-using-weight-loss-jabs-must-use-effective-contraception Sat, 07 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/schott-pharma-invests-in-rtu-cartridge-capacity-expansion https://spypharm.com/schott-pharma-invests-in-rtu-cartridge-capacity-expansion Sat, 07 Jun 2025 06:00:17 -0400 spectro https://spypharm.com/adhd-drugs-back-in-the-spotlight-after-study-debunks-rising-prevalence https://spypharm.com/adhd-drugs-back-in-the-spotlight-after-study-debunks-rising-prevalence Sat, 07 Jun 2025 06:00:17 -0400 spectro https://spypharm.com/juvenescence-enhances-ai-drug-discovery-with-ro5-acquisition https://spypharm.com/juvenescence-enhances-ai-drug-discovery-with-ro5-acquisition Sat, 07 Jun 2025 06:00:17 -0400 spectro https://spypharm.com/rfk-jr-looks-to-alter-rare-disease-regulation-by-fast-tracking-drug-approvals https://spypharm.com/rfk-jr-looks-to-alter-rare-disease-regulation-by-fast-tracking-drug-approvals Sat, 07 Jun 2025 06:00:17 -0400 spectro https://spypharm.com/roche-extends-sma-market-lead-with-evrysdi-tablet-approval-in-europe https://spypharm.com/roche-extends-sma-market-lead-with-evrysdi-tablet-approval-in-europe Thu, 05 Jun 2025 06:00:24 -0400 spectro https://spypharm.com/ec-approves-takeda-adc-plus-chemo-for-stage-iib-hodgkins-lymphoma https://spypharm.com/ec-approves-takeda-adc-plus-chemo-for-stage-iib-hodgkins-lymphoma Thu, 05 Jun 2025 06:00:24 -0400 spectro https://spypharm.com/asco25-jjs-trispecific-antibody-shows-100-response-in-phase-i-multiple-myeloma-study https://spypharm.com/asco25-jjs-trispecific-antibody-shows-100-response-in-phase-i-multiple-myeloma-study Thu, 05 Jun 2025 06:00:24 -0400 spectro https://spypharm.com/introducing-ai-into-the-pharma-supply-chain-is-a-journey https://spypharm.com/introducing-ai-into-the-pharma-supply-chain-is-a-journey Thu, 05 Jun 2025 06:00:23 -0400 spectro https://spypharm.com/axxam-and-molecular-health-link-for-therapeutic-targets https://spypharm.com/axxam-and-molecular-health-link-for-therapeutic-targets Thu, 05 Jun 2025 06:00:23 -0400 spectro https://spypharm.com/redwire-gains-aspera-contract-for-space-based-cancer-research https://spypharm.com/redwire-gains-aspera-contract-for-space-based-cancer-research Thu, 05 Jun 2025 06:00:23 -0400 spectro https://spypharm.com/agenus-and-zydus-sign-agreements-for-botensilimab-and-balstilimab https://spypharm.com/agenus-and-zydus-sign-agreements-for-botensilimab-and-balstilimab Thu, 05 Jun 2025 06:00:23 -0400 spectro https://spypharm.com/magazineare-regulators-keeping-pace-with-ai-adoption-in-clinical-trials https://spypharm.com/magazineare-regulators-keeping-pace-with-ai-adoption-in-clinical-trials Thu, 05 Jun 2025 06:00:23 -0400 spectro https://spypharm.com/epro-and-ecoa-digital-solutions-driving-clinical-trials-engagement https://spypharm.com/epro-and-ecoa-digital-solutions-driving-clinical-trials-engagement Thu, 05 Jun 2025 06:00:23 -0400 spectro https://spypharm.com/ascletiss-daily-acne-tablet-set-for-china-review-after-phase-iii-win https://spypharm.com/ascletiss-daily-acne-tablet-set-for-china-review-after-phase-iii-win Thu, 05 Jun 2025 06:00:23 -0400 spectro https://spypharm.com/sanofi-and-regeneron-report-results-from-two-phase-iii-trials-of-copd-treatment https://spypharm.com/sanofi-and-regeneron-report-results-from-two-phase-iii-trials-of-copd-treatment Tue, 03 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/asco25-msds-kras-g12c-drug-shows-early-promise-in-phase-i https://spypharm.com/asco25-msds-kras-g12c-drug-shows-early-promise-in-phase-i Tue, 03 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/zymeworks-zanidatamab-gains-approval-in-china-for-biliary-tract-cancer https://spypharm.com/zymeworks-zanidatamab-gains-approval-in-china-for-biliary-tract-cancer Tue, 03 Jun 2025 06:00:20 -0400 spectro https://spypharm.com/bms-outlays-11bn-to-join-biontechs-development-of-bispecific-cancer-drug https://spypharm.com/bms-outlays-11bn-to-join-biontechs-development-of-bispecific-cancer-drug Tue, 03 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/sanofi-to-expand-immunology-offerings-with-blueprint-medicines https://spypharm.com/sanofi-to-expand-immunology-offerings-with-blueprint-medicines Tue, 03 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/circode-biomed-gains-clearance-from-fda-for-rna-drug-hm2002 https://spypharm.com/circode-biomed-gains-clearance-from-fda-for-rna-drug-hm2002 Tue, 03 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/asco25-jjs-carvykti-shows-strong-efficacy-across-multiple-myeloma-risk-groups https://spypharm.com/asco25-jjs-carvykti-shows-strong-efficacy-across-multiple-myeloma-risk-groups Tue, 03 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/asco25-regeneron-unpacks-positive-libtayo-data-in-adjuvant-cscc-as-keytruda-stumbles https://spypharm.com/asco25-regeneron-unpacks-positive-libtayo-data-in-adjuvant-cscc-as-keytruda-stumbles Tue, 03 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/regeneron-to-acquire-rights-for-hansohs-hs-20094-therapy https://spypharm.com/regeneron-to-acquire-rights-for-hansohs-hs-20094-therapy Tue, 03 Jun 2025 06:00:17 -0400 spectro https://spypharm.com/asco25-amgens-nplate-proves-effective-in-gi-cancer-linked-thrombocytopaenia https://spypharm.com/asco25-amgens-nplate-proves-effective-in-gi-cancer-linked-thrombocytopaenia Tue, 03 Jun 2025 06:00:17 -0400 spectro https://spypharm.com/alvotech-and-advanz-to-commercialise-biosimilars-in-europe https://spypharm.com/alvotech-and-advanz-to-commercialise-biosimilars-in-europe Sun, 01 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/fda-rejects-stealth-bios-barth-syndrome-treatment-after-165-month-review https://spypharm.com/fda-rejects-stealth-bios-barth-syndrome-treatment-after-165-month-review Sun, 01 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/astellas-and-evopoint-sign-adc-licensing-deal https://spypharm.com/astellas-and-evopoint-sign-adc-licensing-deal Sun, 01 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/daiichi-sankyo-and-msd-withdraw-us-bla-for-lung-cancer-treatment https://spypharm.com/daiichi-sankyo-and-msd-withdraw-us-bla-for-lung-cancer-treatment Sun, 01 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/asco25-pfizers-braftovi-combo-boasts-47-drop-in-disease-progression-in-mcrc https://spypharm.com/asco25-pfizers-braftovi-combo-boasts-47-drop-in-disease-progression-in-mcrc Sun, 01 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/eyepoint-advances-with-duravyu-phase-iii-trial https://spypharm.com/eyepoint-advances-with-duravyu-phase-iii-trial Sun, 01 Jun 2025 06:00:18 -0400 spectro https://spypharm.com/ec-approves-bms-nivolumab-sc-formulation-for-solid-tumours https://spypharm.com/ec-approves-bms-nivolumab-sc-formulation-for-solid-tumours Fri, 30 May 2025 06:00:20 -0400 spectro https://spypharm.com/asco25-merck-kgaa-to-seek-approval-of-tgct-drug-after-phase-iii-success https://spypharm.com/asco25-merck-kgaa-to-seek-approval-of-tgct-drug-after-phase-iii-success Fri, 30 May 2025 06:00:20 -0400 spectro https://spypharm.com/scynexis-resumes-dosing-in-phase-iii-mario-study-after-lengthy-delay https://spypharm.com/scynexis-resumes-dosing-in-phase-iii-mario-study-after-lengthy-delay Fri, 30 May 2025 06:00:20 -0400 spectro https://spypharm.com/daiichi-sankyo-and-msd-withdraw-us-application-for-lung-cancer-bla https://spypharm.com/daiichi-sankyo-and-msd-withdraw-us-application-for-lung-cancer-bla Fri, 30 May 2025 06:00:19 -0400 spectro https://spypharm.com/hhs-cancels-766m-bird-flu-vaccine-contract-with-moderna https://spypharm.com/hhs-cancels-766m-bird-flu-vaccine-contract-with-moderna Fri, 30 May 2025 06:00:19 -0400 spectro https://spypharm.com/the-impact-of-drug-pricing-and-reimbursement-on-the-pharmaceutical-industry https://spypharm.com/the-impact-of-drug-pricing-and-reimbursement-on-the-pharmaceutical-industry Fri, 30 May 2025 06:00:19 -0400 spectro https://spypharm.com/solid-tumours-car-t-therapies-waterloo https://spypharm.com/solid-tumours-car-t-therapies-waterloo Fri, 30 May 2025 06:00:19 -0400 spectro https://spypharm.com/regeneron-to-deploy-telesis-bios-gibson-sola-at-rd-facilities https://spypharm.com/regeneron-to-deploy-telesis-bios-gibson-sola-at-rd-facilities Fri, 30 May 2025 06:00:19 -0400 spectro https://spypharm.com/iteos-to-shut-down-following-2bn-gsk-partnered-tigit-asset-failure https://spypharm.com/iteos-to-shut-down-following-2bn-gsk-partnered-tigit-asset-failure Fri, 30 May 2025 06:00:19 -0400 spectro https://spypharm.com/fda-approves-etons-application-for-hydrocortisone-oral-solution https://spypharm.com/fda-approves-etons-application-for-hydrocortisone-oral-solution Fri, 30 May 2025 06:00:19 -0400 spectro https://spypharm.com/gsk-makes-new-drug-submission-for-depemokimab-in-canada https://spypharm.com/gsk-makes-new-drug-submission-for-depemokimab-in-canada Wed, 28 May 2025 06:00:22 -0400 spectro https://spypharm.com/whats-been-agreed-at-this-years-world-health-assembly https://spypharm.com/whats-been-agreed-at-this-years-world-health-assembly Wed, 28 May 2025 06:00:22 -0400 spectro https://spypharm.com/lupin-partners-steincares-to-commercialise-biosimilar-in-latam https://spypharm.com/lupin-partners-steincares-to-commercialise-biosimilar-in-latam Wed, 28 May 2025 06:00:22 -0400 spectro https://spypharm.com/fda-to-review-otsukas-sibeprenlimab-application-for-igan https://spypharm.com/fda-to-review-otsukas-sibeprenlimab-application-for-igan Wed, 28 May 2025 06:00:22 -0400 spectro https://spypharm.com/ema-validates-solenos-application-for-prader-willi-syndrome-treatment https://spypharm.com/ema-validates-solenos-application-for-prader-willi-syndrome-treatment Wed, 28 May 2025 06:00:22 -0400 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2025-upperton-pharma-solutions https://spypharm.com/pharmaceutical-technology-excellence-awards-2025-upperton-pharma-solutions Wed, 28 May 2025 06:00:22 -0400 spectro https://spypharm.com/biogen-and-city-therapeutics-to-develop-rnai-therapy https://spypharm.com/biogen-and-city-therapeutics-to-develop-rnai-therapy Wed, 28 May 2025 06:00:21 -0400 spectro https://spypharm.com/how-the-cell-and-gene-therapy-market-is-taking-shape https://spypharm.com/how-the-cell-and-gene-therapy-market-is-taking-shape Wed, 28 May 2025 06:00:21 -0400 spectro https://spypharm.com/eli-lilly-to-expand-pain-pipeline-with-1bn-siteone-buyout https://spypharm.com/eli-lilly-to-expand-pain-pipeline-with-1bn-siteone-buyout Wed, 28 May 2025 06:00:21 -0400 spectro https://spypharm.com/capitalising-on-uks-goal-to-become-a-world-leading-clinical-trial-destination https://spypharm.com/capitalising-on-uks-goal-to-become-a-world-leading-clinical-trial-destination Wed, 28 May 2025 06:00:21 -0400 spectro https://spypharm.com/chinas-cde-grants-breakthrough-status-approval-to-abbiskos-hcc-therapy https://spypharm.com/chinas-cde-grants-breakthrough-status-approval-to-abbiskos-hcc-therapy Mon, 26 May 2025 06:00:17 -0400 spectro https://spypharm.com/chmp-recommends-gsks-blenrep-approval-for-multiple-myeloma-treatment https://spypharm.com/chmp-recommends-gsks-blenrep-approval-for-multiple-myeloma-treatment Mon, 26 May 2025 06:00:17 -0400 spectro https://spypharm.com/sanofi-buys-vigil-neuroscience-for-470m-in-alzheimers-push https://spypharm.com/sanofi-buys-vigil-neuroscience-for-470m-in-alzheimers-push Sat, 24 May 2025 06:00:19 -0400 spectro https://spypharm.com/paratek-expands-commercial-portfolio-with-optinose https://spypharm.com/paratek-expands-commercial-portfolio-with-optinose Sat, 24 May 2025 06:00:19 -0400 spectro https://spypharm.com/aptar-digital-to-use-astrazenecas-ai-algorithms-for-ckd-detection https://spypharm.com/aptar-digital-to-use-astrazenecas-ai-algorithms-for-ckd-detection Sat, 24 May 2025 06:00:19 -0400 spectro https://spypharm.com/genentech-to-onshore-us-manufacturing-amid-rising-drug-pricing-tensions https://spypharm.com/genentech-to-onshore-us-manufacturing-amid-rising-drug-pricing-tensions Sat, 24 May 2025 06:00:18 -0400 spectro https://spypharm.com/asco25-roches-itovebi-combo-reduces-risk-of-death-in-breast-cancer-by-33 https://spypharm.com/asco25-roches-itovebi-combo-reduces-risk-of-death-in-breast-cancer-by-33 Sat, 24 May 2025 06:00:18 -0400 spectro https://spypharm.com/nice-endorses-csl-vifors-sparsentan-for-iga-nephropathy-in-adults https://spypharm.com/nice-endorses-csl-vifors-sparsentan-for-iga-nephropathy-in-adults Sat, 24 May 2025 06:00:18 -0400 spectro https://spypharm.com/obesity-therapies-and-the-multi-indication-momentum-how-industry-is-responding https://spypharm.com/obesity-therapies-and-the-multi-indication-momentum-how-industry-is-responding Sat, 24 May 2025 06:00:18 -0400 spectro https://spypharm.com/fda-approves-gsks-nucala-to-treat-copd https://spypharm.com/fda-approves-gsks-nucala-to-treat-copd Sat, 24 May 2025 06:00:18 -0400 spectro https://spypharm.com/medicaid-on-a-spit-after-republicans-budget-bill-passes-house-by-single-vote https://spypharm.com/medicaid-on-a-spit-after-republicans-budget-bill-passes-house-by-single-vote Sat, 24 May 2025 06:00:18 -0400 spectro https://spypharm.com/bayers-eylea-set-for-longer-treatment-intervals-to-challenge-roches-vabysmo https://spypharm.com/bayers-eylea-set-for-longer-treatment-intervals-to-challenge-roches-vabysmo Sat, 24 May 2025 06:00:18 -0400 spectro https://spypharm.com/biontech-to-invest-up-to-134bn-in-uk-rd https://spypharm.com/biontech-to-invest-up-to-134bn-in-uk-rd Thu, 22 May 2025 06:00:20 -0400 spectro https://spypharm.com/orionis-and-genentech-link-on-oncology-small-molecule-glue-medicines https://spypharm.com/orionis-and-genentech-link-on-oncology-small-molecule-glue-medicines Thu, 22 May 2025 06:00:18 -0400 spectro https://spypharm.com/moderna-shares-down-after-pulling-covid-flu-combo-vaccine-application https://spypharm.com/moderna-shares-down-after-pulling-covid-flu-combo-vaccine-application Thu, 22 May 2025 06:00:18 -0400 spectro https://spypharm.com/can-pharma-tariffs-make-america-manufacture-again https://spypharm.com/can-pharma-tariffs-make-america-manufacture-again Thu, 22 May 2025 06:00:18 -0400 spectro https://spypharm.com/vizai-sanofi-and-regeneron-to-link-for-copd-management https://spypharm.com/vizai-sanofi-and-regeneron-to-link-for-copd-management Thu, 22 May 2025 06:00:18 -0400 spectro https://spypharm.com/who-secures-20-funding-increase-amid-us-shortfall https://spypharm.com/who-secures-20-funding-increase-amid-us-shortfall Thu, 22 May 2025 06:00:18 -0400 spectro https://spypharm.com/ats-2025-gsk-strengthens-argument-for-twice-annual-depemokimab https://spypharm.com/ats-2025-gsk-strengthens-argument-for-twice-annual-depemokimab Thu, 22 May 2025 06:00:18 -0400 spectro https://spypharm.com/navigating-new-eu-regulations-in-the-clinical-supply-chain https://spypharm.com/navigating-new-eu-regulations-in-the-clinical-supply-chain Thu, 22 May 2025 06:00:18 -0400 spectro https://spypharm.com/ats-2025-real-world-cohort-study-aligns-with-gsk-depemokimab-narrative https://spypharm.com/ats-2025-real-world-cohort-study-aligns-with-gsk-depemokimab-narrative Thu, 22 May 2025 06:00:18 -0400 spectro https://spypharm.com/overcoming-cold-chain-logistical-challenges-when-delivering-life-saving-ms-therapies https://spypharm.com/overcoming-cold-chain-logistical-challenges-when-delivering-life-saving-ms-therapies Thu, 22 May 2025 06:00:17 -0400 spectro https://spypharm.com/fda-approves-incytes-retifanlimab-combo-for-scac-treatment https://spypharm.com/fda-approves-incytes-retifanlimab-combo-for-scac-treatment Tue, 20 May 2025 06:00:21 -0400 spectro https://spypharm.com/apnimed-to-seek-approval-for-sleep-apnoea-pill-after-phase-iii-success https://spypharm.com/apnimed-to-seek-approval-for-sleep-apnoea-pill-after-phase-iii-success Tue, 20 May 2025 06:00:21 -0400 spectro https://spypharm.com/five-years-one-approval-europes-slow-march-on-alzheimers-treatments https://spypharm.com/five-years-one-approval-europes-slow-march-on-alzheimers-treatments Tue, 20 May 2025 06:00:21 -0400 spectro https://spypharm.com/ats-2025-real-world-data-supports-trikafta-as-gold-standard-in-long-term-cf-care https://spypharm.com/ats-2025-real-world-data-supports-trikafta-as-gold-standard-in-long-term-cf-care Tue, 20 May 2025 06:00:20 -0400 spectro https://spypharm.com/pfizer-signs-global-licensing-deal-with-3sbio-for-bispecific-antibody https://spypharm.com/pfizer-signs-global-licensing-deal-with-3sbio-for-bispecific-antibody Tue, 20 May 2025 06:00:20 -0400 spectro https://spypharm.com/regeneron-buys-bankrupt-23andme-for-256m https://spypharm.com/regeneron-buys-bankrupt-23andme-for-256m Tue, 20 May 2025 06:00:20 -0400 spectro https://spypharm.com/ats-2025-tezepelumab-reduces-copd-exacerbations-in-eosinophilic-patients-despite-cb https://spypharm.com/ats-2025-tezepelumab-reduces-copd-exacerbations-in-eosinophilic-patients-despite-cb Tue, 20 May 2025 06:00:20 -0400 spectro https://spypharm.com/ats-2025-nucala-reduces-copd-exacerbations-regardless-of-severe-event-history https://spypharm.com/ats-2025-nucala-reduces-copd-exacerbations-regardless-of-severe-event-history Tue, 20 May 2025 06:00:20 -0400 spectro https://spypharm.com/power-of-collaboration-more-pertinent-than-ever-says-pharma-experts https://spypharm.com/power-of-collaboration-more-pertinent-than-ever-says-pharma-experts Tue, 20 May 2025 06:00:20 -0400 spectro https://spypharm.com/pharmas-ai-prospects-get-nudged-into-the-future-with-eus-ai-act https://spypharm.com/pharmas-ai-prospects-get-nudged-into-the-future-with-eus-ai-act Sun, 18 May 2025 06:00:18 -0400 spectro https://spypharm.com/trump-revives-plan-for-irp-use-in-us-via-mfn-executive-order https://spypharm.com/trump-revives-plan-for-irp-use-in-us-via-mfn-executive-order Sun, 18 May 2025 06:00:18 -0400 spectro https://spypharm.com/influence-of-high-energy-milling-on-the-biological-activity-of-microbial-particles https://spypharm.com/influence-of-high-energy-milling-on-the-biological-activity-of-microbial-particles Sun, 18 May 2025 06:00:18 -0400 spectro https://spypharm.com/fda-approves-amneals-dhe-migrainecluster-headache-autoinjector https://spypharm.com/fda-approves-amneals-dhe-migrainecluster-headache-autoinjector Sun, 18 May 2025 06:00:18 -0400 spectro https://spypharm.com/agc-biologics-and-quell-to-progress-treg-cell-therapy-development https://spypharm.com/agc-biologics-and-quell-to-progress-treg-cell-therapy-development Sun, 18 May 2025 06:00:18 -0400 spectro https://spypharm.com/newborn-screening-strategy-needs-modernising-as-hhs-disbands-advisory-committee https://spypharm.com/newborn-screening-strategy-needs-modernising-as-hhs-disbands-advisory-committee Sun, 18 May 2025 06:00:18 -0400 spectro https://spypharm.com/revamping-us-pharma-manufacturing-trumps-executive-order-faces-industry-doubts https://spypharm.com/revamping-us-pharma-manufacturing-trumps-executive-order-faces-industry-doubts Sun, 18 May 2025 06:00:18 -0400 spectro https://spypharm.com/fda-biosimilar-approvals-set-for-record-breaking-year-amid-us-pricing-reforms https://spypharm.com/fda-biosimilar-approvals-set-for-record-breaking-year-amid-us-pricing-reforms Sun, 18 May 2025 06:00:18 -0400 spectro https://spypharm.com/eli-lilly-strikes-13bn-gene-therapy-deal-with-rznomics https://spypharm.com/eli-lilly-strikes-13bn-gene-therapy-deal-with-rznomics Sun, 18 May 2025 06:00:17 -0400 spectro https://spypharm.com/podcast-ai-and-supervised-machine-learning-in-clinical-trials-ep1 https://spypharm.com/podcast-ai-and-supervised-machine-learning-in-clinical-trials-ep1 Fri, 16 May 2025 06:00:22 -0400 spectro https://spypharm.com/sanofi-commits-at-least-20bn-to-us-manufacturing-through-2030 https://spypharm.com/sanofi-commits-at-least-20bn-to-us-manufacturing-through-2030 Fri, 16 May 2025 06:00:22 -0400 spectro https://spypharm.com/abbvie-expands-sirna-push-with-335m-adarx-deal https://spypharm.com/abbvie-expands-sirna-push-with-335m-adarx-deal Fri, 16 May 2025 06:00:22 -0400 spectro https://spypharm.com/introducing-the-pharmaceutical-technology-excellence-awards-2025 https://spypharm.com/introducing-the-pharmaceutical-technology-excellence-awards-2025 Fri, 16 May 2025 06:00:22 -0400 spectro https://spypharm.com/engineering-the-future-how-robotics-and-automation-are-transforming-pharmaceutical-logistics https://spypharm.com/engineering-the-future-how-robotics-and-automation-are-transforming-pharmaceutical-logistics Fri, 16 May 2025 06:00:22 -0400 spectro https://spypharm.com/are-regulators-keeping-pace-with-ai-adoption-in-clinical-trials https://spypharm.com/are-regulators-keeping-pace-with-ai-adoption-in-clinical-trials Fri, 16 May 2025 06:00:21 -0400 spectro https://spypharm.com/pathos-ai-raises-365m-for-oncology-drug-development https://spypharm.com/pathos-ai-raises-365m-for-oncology-drug-development Fri, 16 May 2025 06:00:21 -0400 spectro https://spypharm.com/fda-awards-cancer-drug-approvals-to-abbvie-and-msd https://spypharm.com/fda-awards-cancer-drug-approvals-to-abbvie-and-msd Fri, 16 May 2025 06:00:21 -0400 spectro https://spypharm.com/fda-awards-biocrysts-orladeyo-nda-for-paediatric-hae https://spypharm.com/fda-awards-biocrysts-orladeyo-nda-for-paediatric-hae Fri, 16 May 2025 06:00:21 -0400 spectro https://spypharm.com/green-chemistry-navigating-growing-esg-challenges-in-pharma-manufacturing https://spypharm.com/green-chemistry-navigating-growing-esg-challenges-in-pharma-manufacturing Fri, 16 May 2025 06:00:21 -0400 spectro https://spypharm.com/japans-mhlw-approves-sareptas-gene-therapy-for-dmd https://spypharm.com/japans-mhlw-approves-sareptas-gene-therapy-for-dmd Wed, 14 May 2025 06:00:19 -0400 spectro https://spypharm.com/reducing-patient-burden-in-rare-disease-trials-dcts-for-increased-patient-centricity https://spypharm.com/reducing-patient-burden-in-rare-disease-trials-dcts-for-increased-patient-centricity Wed, 14 May 2025 06:00:19 -0400 spectro https://spypharm.com/fda-clears-ensomas-application-for-rare-genetic-disorder-treatment https://spypharm.com/fda-clears-ensomas-application-for-rare-genetic-disorder-treatment Wed, 14 May 2025 06:00:19 -0400 spectro https://spypharm.com/pharma-faces-30-day-deadline-under-trumps-pricing-order https://spypharm.com/pharma-faces-30-day-deadline-under-trumps-pricing-order Wed, 14 May 2025 06:00:19 -0400 spectro https://spypharm.com/ec-grants-orphan-drug-status-to-biodexas-oral-fap-treatment https://spypharm.com/ec-grants-orphan-drug-status-to-biodexas-oral-fap-treatment Wed, 14 May 2025 06:00:19 -0400 spectro https://spypharm.com/republicans-proposed-medicaid-cuts-met-with-dismay https://spypharm.com/republicans-proposed-medicaid-cuts-met-with-dismay Wed, 14 May 2025 06:00:19 -0400 spectro https://spypharm.com/orphan-drug-market-access-in-europe-hta-challenges-and-the-growing-potential-of-rwe https://spypharm.com/orphan-drug-market-access-in-europe-hta-challenges-and-the-growing-potential-of-rwe Wed, 14 May 2025 06:00:19 -0400 spectro https://spypharm.com/how-to-transform-ehr-data-into-useful-clinical-insights-using-ai https://spypharm.com/how-to-transform-ehr-data-into-useful-clinical-insights-using-ai Wed, 14 May 2025 06:00:19 -0400 spectro https://spypharm.com/abeona-secures-cash-runway-with-155m-priority-review-voucher-sale https://spypharm.com/abeona-secures-cash-runway-with-155m-priority-review-voucher-sale Wed, 14 May 2025 06:00:19 -0400 spectro https://spypharm.com/gsk-and-iteos-drop-anti-tigit-drug-following-trial-failure https://spypharm.com/gsk-and-iteos-drop-anti-tigit-drug-following-trial-failure Wed, 14 May 2025 06:00:18 -0400 spectro https://spypharm.com/american-academy-of-neurology-aan-annual-meeting-2025 https://spypharm.com/american-academy-of-neurology-aan-annual-meeting-2025 Mon, 12 May 2025 06:00:19 -0400 spectro https://spypharm.com/lilly-purdue-partnership-to-invest-250m-in-pharma-innovation https://spypharm.com/lilly-purdue-partnership-to-invest-250m-in-pharma-innovation Mon, 12 May 2025 06:00:18 -0400 spectro https://spypharm.com/vc-firm-vivo-capital-outlays-740m-for-biotech-investment https://spypharm.com/vc-firm-vivo-capital-outlays-740m-for-biotech-investment Sat, 10 May 2025 06:00:18 -0400 spectro https://spypharm.com/biovaxys-and-sona-partner-to-develop-cancer-therapeutics https://spypharm.com/biovaxys-and-sona-partner-to-develop-cancer-therapeutics Sat, 10 May 2025 06:00:18 -0400 spectro https://spypharm.com/newbiologix-licenses-cell-line-technology-to-recipharm-advanced-bio https://spypharm.com/newbiologix-licenses-cell-line-technology-to-recipharm-advanced-bio Sat, 10 May 2025 06:00:17 -0400 spectro https://spypharm.com/fda-chief-martin-makary-sets-june-deadline-for-genai-rollout https://spypharm.com/fda-chief-martin-makary-sets-june-deadline-for-genai-rollout Sat, 10 May 2025 06:00:17 -0400 spectro https://spypharm.com/haya-secures-65m-in-series-a-funds-to-advance-heart-failure-treatment https://spypharm.com/haya-secures-65m-in-series-a-funds-to-advance-heart-failure-treatment Sat, 10 May 2025 06:00:17 -0400 spectro https://spypharm.com/sanofi-exec-tells-biotechs-not-to-scrimp-on-clinical-trial-design https://spypharm.com/sanofi-exec-tells-biotechs-not-to-scrimp-on-clinical-trial-design Sat, 10 May 2025 06:00:17 -0400 spectro https://spypharm.com/viralgen-and-trogenix-to-progress-gene-therapy-for-glioblastoma https://spypharm.com/viralgen-and-trogenix-to-progress-gene-therapy-for-glioblastoma Sat, 10 May 2025 06:00:17 -0400 spectro https://spypharm.com/5eu-q1-2024-versus-2025-pricing-shifts-hta-outcomes-and-innovative-drug-trends https://spypharm.com/5eu-q1-2024-versus-2025-pricing-shifts-hta-outcomes-and-innovative-drug-trends Sat, 10 May 2025 06:00:17 -0400 spectro https://spypharm.com/hls-therapeutics-and-esperion-partner-to-commercialise-oral-cardiovascular-medicines https://spypharm.com/hls-therapeutics-and-esperion-partner-to-commercialise-oral-cardiovascular-medicines Sat, 10 May 2025 06:00:17 -0400 spectro https://spypharm.com/bavarian-nordic-shares-rise-7-following-strong-q1-for-vaccine-sales https://spypharm.com/bavarian-nordic-shares-rise-7-following-strong-q1-for-vaccine-sales Sat, 10 May 2025 06:00:17 -0400 spectro https://spypharm.com/ars-pharmas-epinephrine-nasal-spray-1mg-now-available-in-us https://spypharm.com/ars-pharmas-epinephrine-nasal-spray-1mg-now-available-in-us Thu, 08 May 2025 06:00:18 -0400 spectro https://spypharm.com/european-biotechs-must-understand-us-culture-while-seeking-funding https://spypharm.com/european-biotechs-must-understand-us-culture-while-seeking-funding Thu, 08 May 2025 06:00:18 -0400 spectro https://spypharm.com/fda-grants-rmat-status-to-opus-genetics-opgx-lca5-gene-therapy https://spypharm.com/fda-grants-rmat-status-to-opus-genetics-opgx-lca5-gene-therapy Thu, 08 May 2025 06:00:18 -0400 spectro https://spypharm.com/solve-fshd-to-invest-in-armatus-bio-for-arm-201-development https://spypharm.com/solve-fshd-to-invest-in-armatus-bio-for-arm-201-development Thu, 08 May 2025 06:00:18 -0400 spectro https://spypharm.com/ec-approves-astrazenecas-calquence-combo-to-treat-mcl https://spypharm.com/ec-approves-astrazenecas-calquence-combo-to-treat-mcl Thu, 08 May 2025 06:00:18 -0400 spectro https://spypharm.com/overcoming-challenges-in-orphan-drug-development-from-clinical-trials-to-market https://spypharm.com/overcoming-challenges-in-orphan-drug-development-from-clinical-trials-to-market Thu, 08 May 2025 06:00:18 -0400 spectro https://spypharm.com/fda-plans-to-expand-unannounced-inspections-of-foreign-drug-plants https://spypharm.com/fda-plans-to-expand-unannounced-inspections-of-foreign-drug-plants Thu, 08 May 2025 06:00:18 -0400 spectro https://spypharm.com/novo-nordisk-cuts-2025-outlook-due-to-compounding-hit-wegovy-demand https://spypharm.com/novo-nordisk-cuts-2025-outlook-due-to-compounding-hit-wegovy-demand Thu, 08 May 2025 06:00:18 -0400 spectro https://spypharm.com/sarepta-shares-fall-amid-fdas-cber-appointment-and-weak-elevidys-sales https://spypharm.com/sarepta-shares-fall-amid-fdas-cber-appointment-and-weak-elevidys-sales Thu, 08 May 2025 06:00:18 -0400 spectro https://spypharm.com/expediting-parallel-drug-approval-pathways-is-challenging-but-rewarding https://spypharm.com/expediting-parallel-drug-approval-pathways-is-challenging-but-rewarding Thu, 08 May 2025 06:00:18 -0400 spectro https://spypharm.com/swiss-biotech-sectors-rd-investment-grew-in-2024-despite-global-trends https://spypharm.com/swiss-biotech-sectors-rd-investment-grew-in-2024-despite-global-trends Tue, 06 May 2025 06:00:18 -0400 spectro https://spypharm.com/fda-approves-selarsdi-injection-as-interchangeable-with-stelara https://spypharm.com/fda-approves-selarsdi-injection-as-interchangeable-with-stelara Tue, 06 May 2025 06:00:18 -0400 spectro https://spypharm.com/chinese-regulator-grants-priority-review-for-innocares-solid-tumour-treatment https://spypharm.com/chinese-regulator-grants-priority-review-for-innocares-solid-tumour-treatment Tue, 06 May 2025 06:00:18 -0400 spectro https://spypharm.com/fda-accepts-novo-nordisks-nda-submission-for-weight-management-therapy https://spypharm.com/fda-accepts-novo-nordisks-nda-submission-for-weight-management-therapy Tue, 06 May 2025 06:00:18 -0400 spectro https://spypharm.com/tae-life-sciences-ohio-state-university-partner-to-advance-cancer-drug-development https://spypharm.com/tae-life-sciences-ohio-state-university-partner-to-advance-cancer-drug-development Tue, 06 May 2025 06:00:18 -0400 spectro https://spypharm.com/pliant-cuts-workforce-by-45-following-lung-trial-termination https://spypharm.com/pliant-cuts-workforce-by-45-following-lung-trial-termination Sun, 04 May 2025 06:00:17 -0400 spectro https://spypharm.com/mhra-authorises-bavarian-nordics-chikungunya-virus-vaccine https://spypharm.com/mhra-authorises-bavarian-nordics-chikungunya-virus-vaccine Sun, 04 May 2025 06:00:17 -0400 spectro https://spypharm.com/entering-the-era-of-prenatal-gene-therapies https://spypharm.com/entering-the-era-of-prenatal-gene-therapies Sun, 04 May 2025 06:00:17 -0400 spectro https://spypharm.com/hhs-launches-500m-universal-vaccines-initiative https://spypharm.com/hhs-launches-500m-universal-vaccines-initiative Sun, 04 May 2025 06:00:17 -0400 spectro https://spypharm.com/fda-awards-rmat-status-to-4dmt-diabetic-macular-oedema-therapy https://spypharm.com/fda-awards-rmat-status-to-4dmt-diabetic-macular-oedema-therapy Sun, 04 May 2025 06:00:17 -0400 spectro https://spypharm.com/q1-earnings-pulse-check-companies-tentative-on-pharma-specific-tariffs https://spypharm.com/q1-earnings-pulse-check-companies-tentative-on-pharma-specific-tariffs Sun, 04 May 2025 06:00:17 -0400 spectro https://spypharm.com/gsk-remains-resilient-on-tariffs-as-q1-sales-rise-4 https://spypharm.com/gsk-remains-resilient-on-tariffs-as-q1-sales-rise-4 Fri, 02 May 2025 06:00:21 -0400 spectro https://spypharm.com/novartis-to-strengthen-renal-disease-portfolio-with-regulus https://spypharm.com/novartis-to-strengthen-renal-disease-portfolio-with-regulus Fri, 02 May 2025 06:00:21 -0400 spectro https://spypharm.com/fda-approves-jjs-imaavy-for-generalised-myasthenia-gravis https://spypharm.com/fda-approves-jjs-imaavy-for-generalised-myasthenia-gravis Fri, 02 May 2025 06:00:21 -0400 spectro https://spypharm.com/dimerix-and-amicus-to-commercialise-dmx-200-in-us https://spypharm.com/dimerix-and-amicus-to-commercialise-dmx-200-in-us Fri, 02 May 2025 06:00:20 -0400 spectro https://spypharm.com/end-to-end-solutions-why-every-link-in-the-pharmaceutical-supply-chain-counts https://spypharm.com/end-to-end-solutions-why-every-link-in-the-pharmaceutical-supply-chain-counts Fri, 02 May 2025 06:00:20 -0400 spectro https://spypharm.com/repare-signs-out-licensing-deal-with-dcx-biotherapeutics https://spypharm.com/repare-signs-out-licensing-deal-with-dcx-biotherapeutics Fri, 02 May 2025 06:00:19 -0400 spectro https://spypharm.com/biogens-q1-revenue-soars-past-estimates-as-rare-disease-pivot-pays-off https://spypharm.com/biogens-q1-revenue-soars-past-estimates-as-rare-disease-pivot-pays-off Fri, 02 May 2025 06:00:19 -0400 spectro https://spypharm.com/new-1bn-cancer-research-hub-planned-for-south-london https://spypharm.com/new-1bn-cancer-research-hub-planned-for-south-london Fri, 02 May 2025 06:00:19 -0400 spectro https://spypharm.com/ptsd-market-expected-to-reach-55bn-across-the-7mm-by-2034 https://spypharm.com/ptsd-market-expected-to-reach-55bn-across-the-7mm-by-2034 Fri, 02 May 2025 06:00:19 -0400 spectro https://spypharm.com/lillys-q1-2025-revenue-jumps-45-but-cvs-shift-boosts-novos-wegovy https://spypharm.com/lillys-q1-2025-revenue-jumps-45-but-cvs-shift-boosts-novos-wegovy Fri, 02 May 2025 06:00:19 -0400 spectro https://spypharm.com/prilenia-and-ferrer-to-commercialise-pridopidine-in-europe https://spypharm.com/prilenia-and-ferrer-to-commercialise-pridopidine-in-europe Wed, 30 Apr 2025 06:00:21 -0400 spectro https://spypharm.com/biohaven-secures-600m-financing-as-it-awaits-fda-prodrug-decision https://spypharm.com/biohaven-secures-600m-financing-as-it-awaits-fda-prodrug-decision Wed, 30 Apr 2025 06:00:21 -0400 spectro https://spypharm.com/ec-conditionally-approves-regenerons-lynozyfic-for-multiple-myeloma https://spypharm.com/ec-conditionally-approves-regenerons-lynozyfic-for-multiple-myeloma Wed, 30 Apr 2025 06:00:21 -0400 spectro https://spypharm.com/construction-begins-on-msds-1bn-biologics-centre-in-delaware-us https://spypharm.com/construction-begins-on-msds-1bn-biologics-centre-in-delaware-us Wed, 30 Apr 2025 06:00:20 -0400 spectro https://spypharm.com/astrazeneca-ceo-calls-for-increased-european-investment-in-pharma https://spypharm.com/astrazeneca-ceo-calls-for-increased-european-investment-in-pharma Wed, 30 Apr 2025 06:00:20 -0400 spectro https://spypharm.com/uk-mhra-authorises-bridgebios-acoramidis-for-attr-cm https://spypharm.com/uk-mhra-authorises-bridgebios-acoramidis-for-attr-cm Wed, 30 Apr 2025 06:00:20 -0400 spectro https://spypharm.com/impending-us-tariffs-signal-uncertain-future-for-global-pharma-says-globaldata https://spypharm.com/impending-us-tariffs-signal-uncertain-future-for-global-pharma-says-globaldata Wed, 30 Apr 2025 06:00:20 -0400 spectro https://spypharm.com/us-tariffs-likely-to-disrupt-drug-development-costs-and-prices-says-globaldata https://spypharm.com/us-tariffs-likely-to-disrupt-drug-development-costs-and-prices-says-globaldata Wed, 30 Apr 2025 06:00:20 -0400 spectro https://spypharm.com/myostatin-inhibitors-target-muscle-loss-prevention-to-fill-gap-in-glp-1ra-market https://spypharm.com/myostatin-inhibitors-target-muscle-loss-prevention-to-fill-gap-in-glp-1ra-market Wed, 30 Apr 2025 06:00:20 -0400 spectro https://spypharm.com/small-biotechs-shoulder-the-burdens-of-an-uncertain-biopharma-sector https://spypharm.com/small-biotechs-shoulder-the-burdens-of-an-uncertain-biopharma-sector Wed, 30 Apr 2025 06:00:20 -0400 spectro https://spypharm.com/china-approves-innocare-pharmas-btk-inhibitor-for-lymphoma https://spypharm.com/china-approves-innocare-pharmas-btk-inhibitor-for-lymphoma Mon, 28 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/granite-bio-secures-100m-in-funding-for-new-antibodies https://spypharm.com/granite-bio-secures-100m-in-funding-for-new-antibodies Sat, 26 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/ec-grants-orphan-drug-designation-to-dyne-therapeutics-dmd-therapy https://spypharm.com/ec-grants-orphan-drug-designation-to-dyne-therapeutics-dmd-therapy Sat, 26 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/top-20-biopharmas-market-cap-rises-6-in-q1-2025-amid-tariff-headwinds https://spypharm.com/top-20-biopharmas-market-cap-rises-6-in-q1-2025-amid-tariff-headwinds Sat, 26 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/msds-gardasil-sales-slide-further-due-to-china-constraints https://spypharm.com/msds-gardasil-sales-slide-further-due-to-china-constraints Sat, 26 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/challenges-in-filling-for-alum-drug-products-what-does-a-cdmo-need-to-successfully-fill-alum-drug-products https://spypharm.com/challenges-in-filling-for-alum-drug-products-what-does-a-cdmo-need-to-successfully-fill-alum-drug-products Sat, 26 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/thermo-fisher-counters-tariffs-with-2bn-investment-into-us-manufacturing https://spypharm.com/thermo-fisher-counters-tariffs-with-2bn-investment-into-us-manufacturing Sat, 26 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/merck-kgaa-nears-35bn-deal-for-springworks https://spypharm.com/merck-kgaa-nears-35bn-deal-for-springworks Sat, 26 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/fda-approves-akesos-monoclonal-antibody-for-nasopharyngeal-carcinoma https://spypharm.com/fda-approves-akesos-monoclonal-antibody-for-nasopharyngeal-carcinoma Sat, 26 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/fda-free-to-pursue-semaglutide-compounders-after-latest-court-ruling https://spypharm.com/fda-free-to-pursue-semaglutide-compounders-after-latest-court-ruling Sat, 26 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/caribou-cuts-pipeline-and-workforce-to-focus-on-lead-car-t-programmes https://spypharm.com/caribou-cuts-pipeline-and-workforce-to-focus-on-lead-car-t-programmes Sat, 26 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/veraxa-to-go-public-in-16bn-spac-deal-with-voyager https://spypharm.com/veraxa-to-go-public-in-16bn-spac-deal-with-voyager Thu, 24 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/synthetic-hormones-and-the-future-of-contraception https://spypharm.com/synthetic-hormones-and-the-future-of-contraception Thu, 24 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/boehringer-to-expand-oncology-presence-with-572m-tessellate-bio-deal https://spypharm.com/boehringer-to-expand-oncology-presence-with-572m-tessellate-bio-deal Thu, 24 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/concertai-and-bayer-to-boost-precision-oncology-with-ai-and-ml-insights https://spypharm.com/concertai-and-bayer-to-boost-precision-oncology-with-ai-and-ml-insights Thu, 24 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/tnf-and-renova-health-use-ai-to-identify-patients-for-glp-1-treatments https://spypharm.com/tnf-and-renova-health-use-ai-to-identify-patients-for-glp-1-treatments Thu, 24 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/editco-bio-secures-access-to-promegas-technologies-in-licensing-deal https://spypharm.com/editco-bio-secures-access-to-promegas-technologies-in-licensing-deal Thu, 24 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/fda-layoffs-and-priority-review-programmes-lapse-disrupt-rare-disease-pipeline https://spypharm.com/fda-layoffs-and-priority-review-programmes-lapse-disrupt-rare-disease-pipeline Thu, 24 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/first-two-medicinal-products-to-undergo-eu-joint-clinical-assessments-announced https://spypharm.com/first-two-medicinal-products-to-undergo-eu-joint-clinical-assessments-announced Thu, 24 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/biogens-friedreichs-ataxia-treatment-authorised-in-uk https://spypharm.com/biogens-friedreichs-ataxia-treatment-authorised-in-uk Thu, 24 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/eli-lilly-sues-mochi-health-and-others-for-deceptive-tirzepatide-marketing https://spypharm.com/eli-lilly-sues-mochi-health-and-others-for-deceptive-tirzepatide-marketing Thu, 24 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/roche-announces-50bn-us-investment-in-pharma-and-diagnostics https://spypharm.com/roche-announces-50bn-us-investment-in-pharma-and-diagnostics Tue, 22 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/fda-grants-breakthrough-status-to-uniqures-huntingtons-disease-therapy https://spypharm.com/fda-grants-breakthrough-status-to-uniqures-huntingtons-disease-therapy Tue, 22 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/uks-mhra-authorises-gsks-blenrep-for-multiple-myeloma-treatment https://spypharm.com/uks-mhra-authorises-gsks-blenrep-for-multiple-myeloma-treatment Tue, 22 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/sanofi-and-regenerons-dupilumab-approved-by-fda-for-urticaria https://spypharm.com/sanofi-and-regenerons-dupilumab-approved-by-fda-for-urticaria Tue, 22 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/eli-lilly-and-bighat-biosciences-ink-ai-antibody-discovery-deal https://spypharm.com/eli-lilly-and-bighat-biosciences-ink-ai-antibody-discovery-deal Sun, 20 Apr 2025 06:00:10 -0400 spectro https://spypharm.com/acip-recommends-gsks-rsv-vaccine-for-at-risk-adults-50-to-59 https://spypharm.com/acip-recommends-gsks-rsv-vaccine-for-at-risk-adults-50-to-59 Fri, 18 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/who-member-states-agree-on-treaty-to-fight-future-pandemics https://spypharm.com/who-member-states-agree-on-treaty-to-fight-future-pandemics Fri, 18 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/podcast-whats-next-for-the-pharma-tariffs https://spypharm.com/podcast-whats-next-for-the-pharma-tariffs Fri, 18 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/trump-order-eases-medicare-price-negotiation-for-small-molecule-drugs https://spypharm.com/trump-order-eases-medicare-price-negotiation-for-small-molecule-drugs Fri, 18 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/glycomine-raises-115m-to-advance-rare-disease-therapy-into-phase-iib https://spypharm.com/glycomine-raises-115m-to-advance-rare-disease-therapy-into-phase-iib Fri, 18 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/eli-lillys-shares-up-as-oral-glp-1ra-scores-in-first-phase-iii-trial https://spypharm.com/eli-lillys-shares-up-as-oral-glp-1ra-scores-in-first-phase-iii-trial Fri, 18 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/fda-to-review-regenerons-sbla-for-aflibercept-injection-8mg https://spypharm.com/fda-to-review-regenerons-sbla-for-aflibercept-injection-8mg Fri, 18 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/big-pharma-pushes-for-european-policy-change-as-tariffs-loom https://spypharm.com/big-pharma-pushes-for-european-policy-change-as-tariffs-loom Fri, 18 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/fda-approves-neurelis-nasal-spray-for-seizures https://spypharm.com/fda-approves-neurelis-nasal-spray-for-seizures Fri, 18 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/bluebird-bio-reaffirms-carlyle-deal-as-ayrmid-misses-deadline https://spypharm.com/bluebird-bio-reaffirms-carlyle-deal-as-ayrmid-misses-deadline Fri, 18 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/coherus-divests-udenyca-franchise-to-intas-for-up-to-5584m https://spypharm.com/coherus-divests-udenyca-franchise-to-intas-for-up-to-5584m Wed, 16 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/how-collaborative-partnerships-are-driving-progress-in-transformative-cell-and-gene-therapies-cgts https://spypharm.com/how-collaborative-partnerships-are-driving-progress-in-transformative-cell-and-gene-therapies-cgts Wed, 16 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/ironwoods-shares-sink-as-fda-demands-new-trial-for-lead-drug https://spypharm.com/ironwoods-shares-sink-as-fda-demands-new-trial-for-lead-drug Wed, 16 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/valnevas-single-dose-chikungunya-vaccine-authorised-in-brazil https://spypharm.com/valnevas-single-dose-chikungunya-vaccine-authorised-in-brazil Wed, 16 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/bms-camzyos-flops-in-phase-iii-non-obstructive-hypertrophic-cardiomyopathy-trial https://spypharm.com/bms-camzyos-flops-in-phase-iii-non-obstructive-hypertrophic-cardiomyopathy-trial Wed, 16 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/do-in-vivo-car-t-cell-therapies-have-the-potential-to-overtake-ex-vivo-car-ts https://spypharm.com/do-in-vivo-car-t-cell-therapies-have-the-potential-to-overtake-ex-vivo-car-ts Wed, 16 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/escmid-global-2025-climate-informed-infectious-disease-risk-management https://spypharm.com/escmid-global-2025-climate-informed-infectious-disease-risk-management Wed, 16 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/the-7mm-atopic-dermatitis-market-to-experience-growth-reaching-224bn-by-2033 https://spypharm.com/the-7mm-atopic-dermatitis-market-to-experience-growth-reaching-224bn-by-2033 Wed, 16 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/boehringer-and-cue-biopharma-to-develop-autoimmune-therapies https://spypharm.com/boehringer-and-cue-biopharma-to-develop-autoimmune-therapies Wed, 16 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/jj-projects-400m-tariff-hit-but-raises-sales-outlook https://spypharm.com/jj-projects-400m-tariff-hit-but-raises-sales-outlook Wed, 16 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/bms-opdivo-combo-approved-in-us-for-hepatocellular-carcinoma https://spypharm.com/bms-opdivo-combo-approved-in-us-for-hepatocellular-carcinoma Mon, 14 Apr 2025 06:00:15 -0400 spectro https://spypharm.com/novartis-commits-23bn-to-us-manufacturing-amid-tariff-threats https://spypharm.com/novartis-commits-23bn-to-us-manufacturing-amid-tariff-threats Sat, 12 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/pluris-immune-cell-expansion-technologies-gain-patents https://spypharm.com/pluris-immune-cell-expansion-technologies-gain-patents Sat, 12 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/fda-to-phase-out-animal-testing-with-ai-and-lab-based-models https://spypharm.com/fda-to-phase-out-animal-testing-with-ai-and-lab-based-models Sat, 12 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/astrazenecas-oral-breast-cancer-drug-truqap-greenlit-for-nhs-use https://spypharm.com/astrazenecas-oral-breast-cancer-drug-truqap-greenlit-for-nhs-use Sat, 12 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/nmpa-approves-bbm-and-takeda-chinas-haemophilia-b-therapy https://spypharm.com/nmpa-approves-bbm-and-takeda-chinas-haemophilia-b-therapy Sat, 12 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/can-ai-replace-medical-writers-experts-say-not-immediately https://spypharm.com/can-ai-replace-medical-writers-experts-say-not-immediately Sat, 12 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/fda-approves-biocon-biologics-bevacizumab-biosimilar-for-cancer https://spypharm.com/fda-approves-biocon-biologics-bevacizumab-biosimilar-for-cancer Sat, 12 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/keros-therapeutics-considers-sale-amid-investor-pressure https://spypharm.com/keros-therapeutics-considers-sale-amid-investor-pressure Sat, 12 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/cingulate-secures-3m-to-advance-once-daily-anxiety-treatment https://spypharm.com/cingulate-secures-3m-to-advance-once-daily-anxiety-treatment Sat, 12 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/tempest-hits-funding-block-for-phase-iii-liver-cancer-drug-in-waiting https://spypharm.com/tempest-hits-funding-block-for-phase-iii-liver-cancer-drug-in-waiting Sat, 12 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/novo-nordisk-outlays-109bn-to-boost-glp-1ra-production-in-brazil https://spypharm.com/novo-nordisk-outlays-109bn-to-boost-glp-1ra-production-in-brazil Thu, 10 Apr 2025 06:00:21 -0400 spectro https://spypharm.com/us-to-impose-tariffs-on-pharmaceutical-imports https://spypharm.com/us-to-impose-tariffs-on-pharmaceutical-imports Thu, 10 Apr 2025 06:00:21 -0400 spectro https://spypharm.com/obesity-related-liver-conditions-understanding-treatment-options https://spypharm.com/obesity-related-liver-conditions-understanding-treatment-options Thu, 10 Apr 2025 06:00:21 -0400 spectro https://spypharm.com/abbvies-upadacitinib-gains-eu-marketing-authorisation-for-gca https://spypharm.com/abbvies-upadacitinib-gains-eu-marketing-authorisation-for-gca Thu, 10 Apr 2025 06:00:21 -0400 spectro https://spypharm.com/fda-approves-injectable-antibiotics-for-b-braun-drug-delivery-system https://spypharm.com/fda-approves-injectable-antibiotics-for-b-braun-drug-delivery-system Thu, 10 Apr 2025 06:00:20 -0400 spectro https://spypharm.com/merida-launches-with-121m-to-target-autoimmune-antibodies https://spypharm.com/merida-launches-with-121m-to-target-autoimmune-antibodies Thu, 10 Apr 2025 06:00:20 -0400 spectro https://spypharm.com/ira-holds-the-scope-to-shape-pharmas-research-strategy-say-experts https://spypharm.com/ira-holds-the-scope-to-shape-pharmas-research-strategy-say-experts Thu, 10 Apr 2025 06:00:20 -0400 spectro https://spypharm.com/60-degrees-and-yale-to-progress-tafenoquin-for-babesiosis https://spypharm.com/60-degrees-and-yale-to-progress-tafenoquin-for-babesiosis Thu, 10 Apr 2025 06:00:20 -0400 spectro https://spypharm.com/pharma-ceos-warn-ec-president-of-risk-of-exodus-to-us https://spypharm.com/pharma-ceos-warn-ec-president-of-risk-of-exodus-to-us Thu, 10 Apr 2025 06:00:20 -0400 spectro https://spypharm.com/beyond-oncology-the-expanding-potential-of-cell-and-gene-therapies https://spypharm.com/beyond-oncology-the-expanding-potential-of-cell-and-gene-therapies Thu, 10 Apr 2025 06:00:20 -0400 spectro https://spypharm.com/rfk-jr-shifts-stance-on-mmr-vaccine-amid-measles-deaths https://spypharm.com/rfk-jr-shifts-stance-on-mmr-vaccine-amid-measles-deaths Tue, 08 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/chinas-nmpa-authorises-santens-glaucoma-treatment-application https://spypharm.com/chinas-nmpa-authorises-santens-glaucoma-treatment-application Tue, 08 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/ec-approves-astrazenecas-imfinzi-combo-for-nsclc https://spypharm.com/ec-approves-astrazenecas-imfinzi-combo-for-nsclc Tue, 08 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/adpd-2025-first-real-world-data-report-for-leqembi-focuses-on-operational-challenges https://spypharm.com/adpd-2025-first-real-world-data-report-for-leqembi-focuses-on-operational-challenges Tue, 08 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/rhythm-seeks-market-expansion-for-imcivree-following-phase-iii-victory https://spypharm.com/rhythm-seeks-market-expansion-for-imcivree-following-phase-iii-victory Tue, 08 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/obesity-drugs-wont-be-covered-by-medicare-under-2026-cms-policy https://spypharm.com/obesity-drugs-wont-be-covered-by-medicare-under-2026-cms-policy Tue, 08 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/ethris-and-lonza-to-develop-mrna-vaccines-for-respiratory-conditions https://spypharm.com/ethris-and-lonza-to-develop-mrna-vaccines-for-respiratory-conditions Tue, 08 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/ec-approves-extension-of-indication-for-janssen-cilags-darzalex https://spypharm.com/ec-approves-extension-of-indication-for-janssen-cilags-darzalex Tue, 08 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/africa-the-clinical-impact-of-the-us-withdrawal-from-who-and-usaid https://spypharm.com/africa-the-clinical-impact-of-the-us-withdrawal-from-who-and-usaid Tue, 08 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/adpd-2025-reporting-of-first-real-world-data-for-leqembi-focuses-on-operational-challenges-and-safety https://spypharm.com/adpd-2025-reporting-of-first-real-world-data-for-leqembi-focuses-on-operational-challenges-and-safety Tue, 08 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/uveitis-market-expected-to-reach-15bn-across-7mm-by-2033 https://spypharm.com/uveitis-market-expected-to-reach-15bn-across-7mm-by-2033 Sun, 06 Apr 2025 06:00:10 -0400 spectro https://spypharm.com/daiichi-and-astrazenecas-enhertu-gains-ec-approval-for-breast-cancers https://spypharm.com/daiichi-and-astrazenecas-enhertu-gains-ec-approval-for-breast-cancers Sun, 06 Apr 2025 06:00:10 -0400 spectro https://spypharm.com/streeting-promises-uk-pharma-quick-action-on-vpag-frustration https://spypharm.com/streeting-promises-uk-pharma-quick-action-on-vpag-frustration Sun, 06 Apr 2025 06:00:10 -0400 spectro https://spypharm.com/fear-and-uncertainty-linger-over-fdas-future-in-wake-of-trump-admins-layoffs https://spypharm.com/fear-and-uncertainty-linger-over-fdas-future-in-wake-of-trump-admins-layoffs Sun, 06 Apr 2025 06:00:10 -0400 spectro https://spypharm.com/fda-awards-odd-status-to-sanofis-rilzabrutinib-for-two-rare-conditions https://spypharm.com/fda-awards-odd-status-to-sanofis-rilzabrutinib-for-two-rare-conditions Fri, 04 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/abpi-calls-on-uk-government-to-resolve-vpag-crisis https://spypharm.com/abpi-calls-on-uk-government-to-resolve-vpag-crisis Fri, 04 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/atsena-closes-150m-in-series-c-round-to-progress-gene-therapy https://spypharm.com/atsena-closes-150m-in-series-c-round-to-progress-gene-therapy Fri, 04 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/io360-summit-car-t-cell-therapy-applications-beyond-blood-cancer https://spypharm.com/io360-summit-car-t-cell-therapy-applications-beyond-blood-cancer Fri, 04 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/neurona-raises-102m-to-advance-cell-therapy-for-drug-resistant-epilepsy https://spypharm.com/neurona-raises-102m-to-advance-cell-therapy-for-drug-resistant-epilepsy Fri, 04 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/io360-summit-improving-car-t-cell-therapy-manufacture-and-accessibility https://spypharm.com/io360-summit-improving-car-t-cell-therapy-manufacture-and-accessibility Fri, 04 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/adpd-2025-dhts-can-detect-disease-progression-in-patients-with-early-parkinsons https://spypharm.com/adpd-2025-dhts-can-detect-disease-progression-in-patients-with-early-parkinsons Fri, 04 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/pharma-industry-dodges-tariff-blow-but-still-braces-for-disruption https://spypharm.com/pharma-industry-dodges-tariff-blow-but-still-braces-for-disruption Fri, 04 Apr 2025 06:00:19 -0400 spectro https://spypharm.com/nbe-therapeutics-opens-adc-research-facility-in-switzerland https://spypharm.com/nbe-therapeutics-opens-adc-research-facility-in-switzerland Fri, 04 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/digital-cognitive-assessments-and-blood-based-biomarkers-in-alzheimers-research https://spypharm.com/digital-cognitive-assessments-and-blood-based-biomarkers-in-alzheimers-research Fri, 04 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/how-will-ai-shape-the-future-of-the-nhs https://spypharm.com/how-will-ai-shape-the-future-of-the-nhs Wed, 02 Apr 2025 06:00:18 -0400 spectro https://spypharm.com/fda-accepts-priority-review-of-apellis-empaveli-snda-for-kidney-diseases https://spypharm.com/fda-accepts-priority-review-of-apellis-empaveli-snda-for-kidney-diseases Wed, 02 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/cns-market-resurgence-a-decade-long-slump-ends-with-80bn-milestone https://spypharm.com/cns-market-resurgence-a-decade-long-slump-ends-with-80bn-milestone Wed, 02 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/bioversys-secures-patent-claims-in-china-for-bv100 https://spypharm.com/bioversys-secures-patent-claims-in-china-for-bv100 Wed, 02 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/acc-25-tirzepatide-influences-clinical-trajectory-of-patients-with-hfpef-and-obesity https://spypharm.com/acc-25-tirzepatide-influences-clinical-trajectory-of-patients-with-hfpef-and-obesity Wed, 02 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/magazine-are-european-biopharma-manufacturers-nearshoring https://spypharm.com/magazine-are-european-biopharma-manufacturers-nearshoring Wed, 02 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/judge-rejects-jjs-9bn-talc-settlement-for-third-time https://spypharm.com/judge-rejects-jjs-9bn-talc-settlement-for-third-time Wed, 02 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/reshoring-efforts-in-us-fmcg-business-begins-but-cost-increases-are-likely https://spypharm.com/reshoring-efforts-in-us-fmcg-business-begins-but-cost-increases-are-likely Wed, 02 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/platform-trials-the-challenges-benefits-and-best-practices-to-maximize-results-with-an-edc-platform https://spypharm.com/platform-trials-the-challenges-benefits-and-best-practices-to-maximize-results-with-an-edc-platform Wed, 02 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/fda-approves-bavarian-nordics-freeze-dried-mpox-and-smallpox-vaccine https://spypharm.com/fda-approves-bavarian-nordics-freeze-dried-mpox-and-smallpox-vaccine Wed, 02 Apr 2025 06:00:17 -0400 spectro https://spypharm.com/ionis-and-sobi-agree-on-olezarsen-commercialisation https://spypharm.com/ionis-and-sobi-agree-on-olezarsen-commercialisation Sat, 29 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/blockbuster-potential-drugs-ruled-the-2024-pipeline-with-53-rise-over-2023 https://spypharm.com/blockbuster-potential-drugs-ruled-the-2024-pipeline-with-53-rise-over-2023 Sat, 29 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/how-bioconjugation-is-unlocking-the-next-generation-of-drug-development https://spypharm.com/how-bioconjugation-is-unlocking-the-next-generation-of-drug-development Sat, 29 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/macau-approves-iaso-bios-multiple-myeloma-therapy https://spypharm.com/macau-approves-iaso-bios-multiple-myeloma-therapy Sat, 29 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/weill-cancer-hub-east-launches-to-transform-treatment https://spypharm.com/weill-cancer-hub-east-launches-to-transform-treatment Sat, 29 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/genmabs-tivdak-approved-in-japan-for-advanced-cervical-cancer https://spypharm.com/genmabs-tivdak-approved-in-japan-for-advanced-cervical-cancer Sat, 29 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/soleno-wins-fda-approval-for-prader-willi-hyperphagia-treatment https://spypharm.com/soleno-wins-fda-approval-for-prader-willi-hyperphagia-treatment Sat, 29 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/hhs-announces-major-workforce-cuts-and-reorganisation https://spypharm.com/hhs-announces-major-workforce-cuts-and-reorganisation Sat, 29 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/novo-nordisk-strikes-1bn-deal-for-lexicons-oral-obesity-drug https://spypharm.com/novo-nordisk-strikes-1bn-deal-for-lexicons-oral-obesity-drug Sat, 29 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/msds-subcutaneous-keytruda-non-inferior-to-iv-version-of-blockbuster-drug https://spypharm.com/msds-subcutaneous-keytruda-non-inferior-to-iv-version-of-blockbuster-drug Sat, 29 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/fda-fast-tracks-sanofis-mrna-vaccine-for-chlamydia https://spypharm.com/fda-fast-tracks-sanofis-mrna-vaccine-for-chlamydia Thu, 27 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/msd-makes-licence-agreement-with-hengrui-pharma-for-lpa-inhibitor https://spypharm.com/msd-makes-licence-agreement-with-hengrui-pharma-for-lpa-inhibitor Thu, 27 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/mhra-launches-new-monthly-safety-bulletins https://spypharm.com/mhra-launches-new-monthly-safety-bulletins Thu, 27 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/cassava-ends-simufilam-alzheimers-programme-after-second-phase-iii-failure https://spypharm.com/cassava-ends-simufilam-alzheimers-programme-after-second-phase-iii-failure Thu, 27 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/character-biosciences-gains-93m-for-precision-eye-disease-therapies https://spypharm.com/character-biosciences-gains-93m-for-precision-eye-disease-therapies Thu, 27 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/eu-health-data-space-strikes-a-chord-in-eu-harmonisation-plans https://spypharm.com/eu-health-data-space-strikes-a-chord-in-eu-harmonisation-plans Thu, 27 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/unmatched-quality-in-pharmaceutical-logistics-why-it-matters https://spypharm.com/unmatched-quality-in-pharmaceutical-logistics-why-it-matters Thu, 27 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/fda-approves-gsks-blujepa-for-uncomplicated-utis https://spypharm.com/fda-approves-gsks-blujepa-for-uncomplicated-utis Thu, 27 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/big-pharma-faces-headwinds-in-china-as-vaccine-sales-decline https://spypharm.com/big-pharma-faces-headwinds-in-china-as-vaccine-sales-decline Thu, 27 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/ec-approves-msds-pneumococcal-21-valent-conjugate-capvaxive https://spypharm.com/ec-approves-msds-pneumococcal-21-valent-conjugate-capvaxive Thu, 27 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/alberta-partners-siemens-and-the-alberta-cancer-foundation https://spypharm.com/alberta-partners-siemens-and-the-alberta-cancer-foundation Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/rising-sirturo-resistance-highlights-urgent-need-for-new-tb-therapies https://spypharm.com/rising-sirturo-resistance-highlights-urgent-need-for-new-tb-therapies Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/fda-approves-ind-application-for-everests-cancer-vaccine https://spypharm.com/fda-approves-ind-application-for-everests-cancer-vaccine Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/astrazeneca-to-invest-25bn-in-rd-centre-in-china https://spypharm.com/astrazeneca-to-invest-25bn-in-rd-centre-in-china Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/jj-boosts-us-operations-with-55bn-investment https://spypharm.com/jj-boosts-us-operations-with-55bn-investment Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/valneva-outlays-40000-vaccines-to-reunion-amidst-chikungunya-surge https://spypharm.com/valneva-outlays-40000-vaccines-to-reunion-amidst-chikungunya-surge Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/augustine-secures-85m-to-advance-charcot-marie-tooth-candidate https://spypharm.com/augustine-secures-85m-to-advance-charcot-marie-tooth-candidate Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/alnylam-challenges-pfizer-and-bridgebio-with-fda-nod-for-attr-cm-drug https://spypharm.com/alnylam-challenges-pfizer-and-bridgebio-with-fda-nod-for-attr-cm-drug Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/sermonix-and-regor-to-enhance-breast-cancer-treatment-options https://spypharm.com/sermonix-and-regor-to-enhance-breast-cancer-treatment-options Tue, 25 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/tempero-secures-70m-to-advance-addiction-treatment-candidate https://spypharm.com/tempero-secures-70m-to-advance-addiction-treatment-candidate Tue, 25 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/european-agencies-catch-up-with-speedier-regulatory-pathways-for-cgts-in-the-us https://spypharm.com/european-agencies-catch-up-with-speedier-regulatory-pathways-for-cgts-in-the-us Sun, 23 Mar 2025 06:00:11 -0400 spectro https://spypharm.com/menarini-to-enhance-bpdcn-detection-with-visualdxs-link https://spypharm.com/menarini-to-enhance-bpdcn-detection-with-visualdxs-link Sun, 23 Mar 2025 06:00:11 -0400 spectro https://spypharm.com/china-conditionally-approves-hutchmeds-tazverik-for-follicular-lymphoma https://spypharm.com/china-conditionally-approves-hutchmeds-tazverik-for-follicular-lymphoma Sun, 23 Mar 2025 06:00:11 -0400 spectro https://spypharm.com/global-funding-cuts-reversing-decades-of-tuberculosis-progress-who-says https://spypharm.com/global-funding-cuts-reversing-decades-of-tuberculosis-progress-who-says Sun, 23 Mar 2025 06:00:11 -0400 spectro https://spypharm.com/how-to-manage-regulatory-complexities-with-clinical-trial-data https://spypharm.com/how-to-manage-regulatory-complexities-with-clinical-trial-data Sun, 23 Mar 2025 06:00:11 -0400 spectro https://spypharm.com/funding-drought-how-can-biotech-and-biopharma-keep-trials-running https://spypharm.com/funding-drought-how-can-biotech-and-biopharma-keep-trials-running Sun, 23 Mar 2025 06:00:11 -0400 spectro https://spypharm.com/pfizer-sells-73-stake-in-haleon-for-33bn https://spypharm.com/pfizer-sells-73-stake-in-haleon-for-33bn Fri, 21 Mar 2025 06:00:20 -0400 spectro https://spypharm.com/oxford-biotherapeutics-and-roche-link-on-antibody-cancer-treatments https://spypharm.com/oxford-biotherapeutics-and-roche-link-on-antibody-cancer-treatments Fri, 21 Mar 2025 06:00:20 -0400 spectro https://spypharm.com/blood-cancers-dominate-car-t-pipeline https://spypharm.com/blood-cancers-dominate-car-t-pipeline Fri, 21 Mar 2025 06:00:20 -0400 spectro https://spypharm.com/allogeneic-cell-therapies-poised-for-prime-time-says-expert https://spypharm.com/allogeneic-cell-therapies-poised-for-prime-time-says-expert Fri, 21 Mar 2025 06:00:20 -0400 spectro https://spypharm.com/uspto-allows-patents-for-remedys-large-hemispheric-infarction-drug https://spypharm.com/uspto-allows-patents-for-remedys-large-hemispheric-infarction-drug Fri, 21 Mar 2025 06:00:20 -0400 spectro https://spypharm.com/fda-approves-johnson-johnsons-tremfya-to-treat-crohns-disease https://spypharm.com/fda-approves-johnson-johnsons-tremfya-to-treat-crohns-disease Fri, 21 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/sanofi-outlays-19bn-to-purchase-dren-bios-bispecific-antibody https://spypharm.com/sanofi-outlays-19bn-to-purchase-dren-bios-bispecific-antibody Fri, 21 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/servier-and-black-diamond-sign-deal-for-solid-tumours-therapy https://spypharm.com/servier-and-black-diamond-sign-deal-for-solid-tumours-therapy Fri, 21 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/international-reference-pricing-irp-2024-a-year-in-review https://spypharm.com/international-reference-pricing-irp-2024-a-year-in-review Fri, 21 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/roches-discontinued-alzheimers-drug-shows-signs-of-preventing-onset https://spypharm.com/roches-discontinued-alzheimers-drug-shows-signs-of-preventing-onset Fri, 21 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/health-canada-approves-biogens-skyclarys-for-friedreichs-ataxia https://spypharm.com/health-canada-approves-biogens-skyclarys-for-friedreichs-ataxia Wed, 19 Mar 2025 06:00:19 -0400 spectro https://spypharm.com/astrazeneca-and-alteogen-agree-on-alt-b4-platform-tech https://spypharm.com/astrazeneca-and-alteogen-agree-on-alt-b4-platform-tech Wed, 19 Mar 2025 06:00:19 -0400 spectro https://spypharm.com/latigo-secures-150m-for-non-opioid-pain-treatment-development https://spypharm.com/latigo-secures-150m-for-non-opioid-pain-treatment-development Wed, 19 Mar 2025 06:00:19 -0400 spectro https://spypharm.com/big-tech-meets-biotech-recursion-and-the-ai-gold-rush-in-pharma https://spypharm.com/big-tech-meets-biotech-recursion-and-the-ai-gold-rush-in-pharma Wed, 19 Mar 2025 06:00:19 -0400 spectro https://spypharm.com/investigating-key-strategies-for-optimising-clinical-trial-supply-chains-in-2025 https://spypharm.com/investigating-key-strategies-for-optimising-clinical-trial-supply-chains-in-2025 Wed, 19 Mar 2025 06:00:19 -0400 spectro https://spypharm.com/incyte-stock-hit-11-despite-paediatric-dermatology-trials-hitting-target https://spypharm.com/incyte-stock-hit-11-despite-paediatric-dermatology-trials-hitting-target Wed, 19 Mar 2025 06:00:19 -0400 spectro https://spypharm.com/clinical-trial-challenges-in-china-how-a-sharp-and-clinschain-pairing-is-breaking-down-barriers https://spypharm.com/clinical-trial-challenges-in-china-how-a-sharp-and-clinschain-pairing-is-breaking-down-barriers Wed, 19 Mar 2025 06:00:19 -0400 spectro https://spypharm.com/curevo-procures-110m-and-former-gsk-exec-for-shingles-vaccine-candidate https://spypharm.com/curevo-procures-110m-and-former-gsk-exec-for-shingles-vaccine-candidate Wed, 19 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/arbor-to-advance-gene-editing-treatments-with-739m-funding https://spypharm.com/arbor-to-advance-gene-editing-treatments-with-739m-funding Wed, 19 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/opko-and-entera-focus-on-oral-care-for-obesity-and-metabolic-disorders https://spypharm.com/opko-and-entera-focus-on-oral-care-for-obesity-and-metabolic-disorders Wed, 19 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/ec-approves-bristol-myers-squibbs-follicular-lymphoma-car-t-therapy https://spypharm.com/ec-approves-bristol-myers-squibbs-follicular-lymphoma-car-t-therapy Mon, 17 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/boehringer-ingelheim-and-salipro-enter-drug-discovery-partnership https://spypharm.com/boehringer-ingelheim-and-salipro-enter-drug-discovery-partnership Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/ec-approves-otsuka-and-lundbecks-rxultifor-schizophrenia https://spypharm.com/ec-approves-otsuka-and-lundbecks-rxultifor-schizophrenia Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/insilico-raises-110m-to-develop-drug-pipeline-and-ai-platform https://spypharm.com/insilico-raises-110m-to-develop-drug-pipeline-and-ai-platform Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/gedeon-richters-once-daily-endometriosis-pill-approved-for-nhs-use https://spypharm.com/gedeon-richters-once-daily-endometriosis-pill-approved-for-nhs-use Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/mallinckrodt-and-endo-sign-67bn-merger-deal https://spypharm.com/mallinckrodt-and-endo-sign-67bn-merger-deal Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/emergent-signs-financial-investment-agreement-with-swiss-rockets https://spypharm.com/emergent-signs-financial-investment-agreement-with-swiss-rockets Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/astrazeneca-director-says-ai-must-be-a-thought-partner-in-drug-discovery https://spypharm.com/astrazeneca-director-says-ai-must-be-a-thought-partner-in-drug-discovery Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/meiragtx-and-hologen-launch-ai-backed-gene-therapy-venture https://spypharm.com/meiragtx-and-hologen-launch-ai-backed-gene-therapy-venture Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/vivani-treats-first-patient-with-long-lasting-drug-implant-for-weight-loss https://spypharm.com/vivani-treats-first-patient-with-long-lasting-drug-implant-for-weight-loss Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/unsafe-and-unregulated-cell-therapies-being-sold-in-europe https://spypharm.com/unsafe-and-unregulated-cell-therapies-being-sold-in-europe Sat, 15 Mar 2025 06:00:21 -0400 spectro https://spypharm.com/vori-health-secures-53m-funding-to-support-musculoskeletal-care https://spypharm.com/vori-health-secures-53m-funding-to-support-musculoskeletal-care Thu, 13 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/zealand-and-roche-strike-53bn-obesity-treatment-deal https://spypharm.com/zealand-and-roche-strike-53bn-obesity-treatment-deal Thu, 13 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/canada-and-alberta-governments-to-invest-in-entos-rd-facility https://spypharm.com/canada-and-alberta-governments-to-invest-in-entos-rd-facility Thu, 13 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/wuxi-xdc-and-abtis-collaborate-on-antibody-drug-conjugates https://spypharm.com/wuxi-xdc-and-abtis-collaborate-on-antibody-drug-conjugates Thu, 13 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/viking-strikes-150m-deal-to-secure-supply-of-obesity-drug https://spypharm.com/viking-strikes-150m-deal-to-secure-supply-of-obesity-drug Thu, 13 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/bms-to-acquire-longtime-cell-therapy-partner-2seventy-bio-for-286m https://spypharm.com/bms-to-acquire-longtime-cell-therapy-partner-2seventy-bio-for-286m Thu, 13 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/atsenas-atsn-201-gains-fda-fast-track-status-for-xlrs-treatment https://spypharm.com/atsenas-atsn-201-gains-fda-fast-track-status-for-xlrs-treatment Thu, 13 Mar 2025 06:00:15 -0400 spectro https://spypharm.com/orphelia-explores-avenues-for-liquid-neuroblastoma-med-after-eu-chmp-rejection https://spypharm.com/orphelia-explores-avenues-for-liquid-neuroblastoma-med-after-eu-chmp-rejection Thu, 13 Mar 2025 06:00:15 -0400 spectro https://spypharm.com/ono-earmarks-940m-to-gain-rare-blood-cancer-therapy-from-ionis https://spypharm.com/ono-earmarks-940m-to-gain-rare-blood-cancer-therapy-from-ionis Thu, 13 Mar 2025 06:00:15 -0400 spectro https://spypharm.com/envirotainer-expands-cold-chain-solutions-portfolio-to-cover-all-pharma-segments-sizes-and-temperatures https://spypharm.com/envirotainer-expands-cold-chain-solutions-portfolio-to-cover-all-pharma-segments-sizes-and-temperatures Thu, 13 Mar 2025 06:00:15 -0400 spectro https://spypharm.com/roche-announces-hub-for-cardiovascular-renal-and-metabolism-research https://spypharm.com/roche-announces-hub-for-cardiovascular-renal-and-metabolism-research Tue, 11 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/alliance-pharma-agrees-to-362m-acquisition-by-dbay https://spypharm.com/alliance-pharma-agrees-to-362m-acquisition-by-dbay Tue, 11 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/ec-approves-bms-opdivo-and-yervoy-combo-for-hcc https://spypharm.com/ec-approves-bms-opdivo-and-yervoy-combo-for-hcc Tue, 11 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/sun-pharma-agrees-to-acquire-checkpoint-therapeutics https://spypharm.com/sun-pharma-agrees-to-acquire-checkpoint-therapeutics Tue, 11 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/kenox-and-lactiga-partner-on-siga-therapies-for-immunodeficiency https://spypharm.com/kenox-and-lactiga-partner-on-siga-therapies-for-immunodeficiency Tue, 11 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/astrazeneca-and-ionis-win-eu-approval-for-attr-polyneuropathy https://spypharm.com/astrazeneca-and-ionis-win-eu-approval-for-attr-polyneuropathy Tue, 11 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/vaccinex-plans-nasdaq-exit-as-alzheimer-market-pressure-grows https://spypharm.com/vaccinex-plans-nasdaq-exit-as-alzheimer-market-pressure-grows Tue, 11 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/artificial-intelligence-is-making-clinical-supply-chains-more-efficient-and-more-sustainable-heres-how https://spypharm.com/artificial-intelligence-is-making-clinical-supply-chains-more-efficient-and-more-sustainable-heres-how Tue, 11 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/ia-2a-positivity-identified-as-a-key-predictor-in-type-1-diabetes-progression https://spypharm.com/ia-2a-positivity-identified-as-a-key-predictor-in-type-1-diabetes-progression Tue, 11 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/fda-odd-given-to-plus-therapeutics-injectable-radiotherapy https://spypharm.com/fda-odd-given-to-plus-therapeutics-injectable-radiotherapy Sun, 09 Mar 2025 06:00:10 -0400 spectro https://spypharm.com/uks-pricing-watchdog-rejects-alzheimer-treatments-for-the-second-time https://spypharm.com/uks-pricing-watchdog-rejects-alzheimer-treatments-for-the-second-time Sun, 09 Mar 2025 06:00:09 -0400 spectro https://spypharm.com/jj-drops-phase-iii-mdd-programme-due-to-lack-of-efficacy https://spypharm.com/jj-drops-phase-iii-mdd-programme-due-to-lack-of-efficacy Sun, 09 Mar 2025 06:00:09 -0400 spectro https://spypharm.com/fda-approves-scpharmaceuticals-furoscix-snda-for-oedema-in-ckd https://spypharm.com/fda-approves-scpharmaceuticals-furoscix-snda-for-oedema-in-ckd Sun, 09 Mar 2025 06:00:09 -0400 spectro https://spypharm.com/the-trillion-dollar-opportunity-in-womens-health https://spypharm.com/the-trillion-dollar-opportunity-in-womens-health Sun, 09 Mar 2025 06:00:09 -0400 spectro https://spypharm.com/astellas-and-yaskawa-form-jv-for-cell-therapy-product-manufacture https://spypharm.com/astellas-and-yaskawa-form-jv-for-cell-therapy-product-manufacture Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/itm-targets-us-approval-for-radiopharmaceutical-after-phase-iii-readout https://spypharm.com/itm-targets-us-approval-for-radiopharmaceutical-after-phase-iii-readout Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/tris-pharma-eyes-approval-after-pain-drug-triumphs-in-second-phase-iii-trial https://spypharm.com/tris-pharma-eyes-approval-after-pain-drug-triumphs-in-second-phase-iii-trial Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/tc-biopharm-signs-loi-to-acquire-ophthalmic-pharma-company https://spypharm.com/tc-biopharm-signs-loi-to-acquire-ophthalmic-pharma-company Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/novo-nordisk-cuts-wegovy-price-through-new-direct-to-patient-online-pharmacy https://spypharm.com/novo-nordisk-cuts-wegovy-price-through-new-direct-to-patient-online-pharmacy Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/trimtech-closes-seed-fund-round-to-advance-cns-therapeutics-pipeline https://spypharm.com/trimtech-closes-seed-fund-round-to-advance-cns-therapeutics-pipeline Fri, 07 Mar 2025 06:00:17 -0500 spectro